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Lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer 
mortality of both genders in the United States. A recent report suggests that the relative five-year 
survival rate of lung cancer is only 18%. Studies indicate many factors are associated with the 
survival of lung cancer patients, including age at diagnosis. It is widely known as a disease of 
older people, but the literature shows a substantial number of young people have been diagnosed 
with lung cancer. The literature also indicates that the refusal of recommended treatment 
contributes to cancer-related death and poorer survival. The objectives of this dissertation were to 
estimate the survival of lung cancer patients, examine the effect of treatment refusal on survival, 
and investigate factors associated with treatment refusal. To address these objectives, we 
conducted our analyses using two large cancer databases: the Veterans Affairs Central Cancer 
Registry and the National Cancer Database. We performed statistical data analyses using logistic 
regression, the Kaplan–Meier survival estimator, and Cox regression (proportional hazards 
regression) method. The results indicate a better five-year survival among younger-onset patients 
compared with older-onset patients, particularly among early-stage cancer. In the multivariable 
analyses, treatment refusal was associated with higher mortality risk. Furthermore, our results 
suggested that patients of older age at diagnosis, female gender, with comorbid conditions, and 





dissertation, we could not analyze other relevant factors, such as types of comorbidity, patient’s 
performance status, treatment side effects, family history of lung cancer, and cost of treatment, 
due to data limitation. Adjusting such factors in future studies will provide a more robust 
comparison of survival and genetic differences between younger- and older-onset lung cancer 
cases. Future studies should also examine patients’ and clinical aspects of cancer education and 











 Lung cancer begins with an abnormal growth of cells of the lung. The disease develops 
following a series of pathological changes in the respiratory epithelium.1 In theory, lung cancer 
grows from a single malignant cell into a detectable lesion.2 At the time of diagnosis, the majority 
of the lung cancer patients are symptomatic. The most common initial symptom is a cough, 
especially if the cancer grows in the central air-way.1,2 When the cancer is located in the 
peripheral part, however, the cough may manifest as a late symptom. Other symptoms include 
bronchorrhea, fever, chills, purulent sputum production, dyspnea, chest pain, hemoptysis, wheeze, 
and stridor.3 The literature suggests that the local tumor growth, regional extension, metastases, 
and a combination of mechanisms causes tumor-associated symptoms.3  
 
Epidemiology of Lung Cancer 
 Globally, lung cancer has had a significant impact on morbidity and mortality for 
decades. The disease has been reported as the most common cancer diagnosed worldwide since 
1985.4 The GLOBOCAN report by the International Agency for Research on Cancer (IARC) in 
2002 indicated that lung cancer accounted for 12% (1.35 million people) of all invasive cancers 
diagnosed worldwide.4 A decade later, the IARC report in 2012 on cancer status worldwide 
suggested an increase in the incidence of lung cancer to 1.8 million cases.5 The last report also 






 Changes in the tobacco epidemic are thought to have affected the global differences in 
lung cancer rates and trends.6,7 In countries such as the United States (US) and the United 
Kingdom, the tobacco epidemic peaked in the middle of the 20th century and the highest 
incidence of lung cancer rates was reported around that period.6,8 Lung cancer incidence has 
declined since the mid-2000s, particularly among men.8 The increase in lung cancer rates among 
women is considered to be the reflection of the increased frequency of smoking among 
women.5,9,10 In countries where the number of smokers continues to increase, such as China, 
Indonesia, and countries in Africa, more cases of lung cancer are anticipated in the next few 
decades.5,6  
 A recent report by the American Cancer Society (ACS) suggests that 234,030 new cases 
of lung cancer will be diagnosed in 2018 in the US.11 The estimation indicates that lung cancer 
contributes to one in seven cancer cases in the country. The report also points out that lung 
cancer-related deaths account for about 25% of all cancer mortality of both sexes.11,12 
Advancements in lung cancer care, such as the use of low-dose spiral computed tomography for 
screening and cancer-targeted therapy based on specific tumor molecular characteristics for a 
treatment option, have contributed to some reduction in disease morbidity and mortality.5,11,13 
However, lung cancer survival remains poor. The estimation made for the five-year relative 
survival of lung cancer cases in the US in 2018 is 18%.12 The survival rate varies between early 
and advanced stages; the five-year survival of local and distant stages were 56% and 5%, 
respectively.12 Many epidemiologic studies have suggested that multiple factors affect lung 
cancer mortality, including, patient characteristics, demographic, tumor clinical, geographic, 






Risk Factors of Lung Cancer 
 A number of risk factors have been associated with lung cancer. Tobacco smoking has 
been reported as the main risk factor.16,17 Other risk factors, such as environmental exposures, 
family history of lung cancer, infection, and other substances exposures, have also suggested an 
increased risk of lung cancer.14,16,17 In addition, the shift in smoking patterns has affected 
individual susceptibility to lung cancer. Evidence of changes in patient characteristics, such as 
age and gender, associated with the tobacco epidemic has been reported.17,18 Details on the 
association of those risk factors and lung cancer are described in the following sections. 
Cigarette Smoking  
 Tobacco mainstream smoke contains a mixture of approximately 4,000 compounds. Of 
those compounds, studies have reported 60–70 carcinogens, such as polycyclic aromatic 
hydrocarbons (PAHs), heterocyclic hydrocarbons, N-nitrosamines, and N-heterocyclic 
amines.19,20 Lung cancer involves interactions between carcinogens and lung tissue. For example, 
the incomplete combustion of tobacco during smoking will produce PAHs, and lung tissue 
metabolizes these components to form mutagenic DNA adducts.2,21 The DNA adduct formation in 
lung tissue is considered the initiating phase of carcinogenesis that leads to lung cancer.21,22 The 
risk of lung cancer among smokers was estimated as 20 times higher than never-smokers.16 
Furthermore, findings from case-control and cohort studies summarized in a paper by Alberg et 
al. indicate the risk of lung cancer increases with the duration of smoking and number of 
cigarettes smoked per day.23  
 Tobacco smoking is associated with more than 80% of lung cancer cases in the US.16,17 In 
studies summarized by Cruz et al., four out of five adult smokers begin to smoke before the age 
of 18 years in the US.17 The chronological trend suggests the average time lag between smoking 
initiation and lung cancer occurrence is approximately 20 years.16,24 Considering the age of 





smoking as adolescents or young adults may be diagnosed with the disease at a younger age than 
the current average age of lung cancer cases, that is 70 years. Nevertheless, the number of 
cigarettes per day also affected this estimation.  
Environmental Exposures 
 Occupational exposures have been reported as the second risk factor of lung cancer 
following cigarette smoking, particularly in industrial countries.16 In many work settings, workers 
are exposed to carcinogens, such as asbestos fiber, silica dust, metals including arsenic and 
chromium, and radiation, which leads to an increased risk of lung cancer and other respiratory 
diseases.5,23,25 Studies reviewed in an article by Alberg et al. indicate that asbestos exposure may 
increase the risk of lung cancer to more than five times higher than non-exposure.16 The risk was 
even higher among smokers due to the synergistic effect between smoking and asbestos 
exposure.17,26  
 Similarly, an increased risk of lung cancer has been suggested due to exposure to high 
linear energy transfer, such as radon, which was frequently reported among uranium miners.16,25 
Studies reviewed in lung cancer literature suggest that approximately 9–15% of lung cancer cases 
were associated with radon exposure.2,16 Radon, a natural soil-derived gas, is also found in 
residential settings, and its presence may be increasing due to the low ventilation rates in indoor 
air. A lack of association between indoor radon exposure and lung cancer was suggested by the 
World Health Organization (WHO) at an exposure level of less than 100 Bq/m3, whereas the 
recommendation from the Environmental Protection Agency for radon exposure in the US was 
148 Bq/m3.27,28 Studies indicate a significant positive linear trend of radon concentration were 
associated with the increasing risk of lung cancer.28-30 For example, a nonsmoker exposed to 200 
Bq/m3 has a risk of developing lung cancer 1.5 times higher than those exposed to 100 Bq/m3; an 
exposure of 400 Bq/m3 would result in three times higher risk.28 A synergistic effect on risk of 





Family History of Lung Cancer 
 Individuals with a positive family history of lung cancer have a higher risk of lung 
cancer,31,32 which may suggest the effect of both shared environmental factors and shared genetic 
factors among family members. Individual factors, such as differences in carcinogen metabolism 
and detoxification, DNA repair, cell cycle control, and inflammation pathways, have been 
suggested to modify susceptibility to lung cancer.2 A meta-analysis of cohort and case-control 
studies reported that positive family history of lung cancer increased individual risk of lung 
cancer by 1.63 times; for those aged less than 50 years, the risk was even higher (odds ratio [OR] 
= 2.08; 95% confidence interval [95% CI]: 1.18–3.63).31 Findings from other studies corroborate 
the results of the association between positive family history of lung cancer and lung cancer 
occurrence, particularly among the young.32-34 Cote et al. reported that a first-degree relative of a 
lung cancer case had a 1.51 times higher risk of lung cancer after adjustment for smoking and 
other covariates (95% CI: 1.39–1.63).35 The study also reported that the association was strongest 
when the lung cancer case is a sibling (OR = 1.82; 95% CI: 1.62–2.05).35  
Infection 
 Studies reviewed in a paper by Cruz et al. suggest that inflammation caused by 
tuberculosis and tuberculosis-related scar contribute to lung cancer pathogenesis.17 In addition, 
patients with HIV infection have been reported to experience a higher risk of lung cancer in 
comparison to non-HIV infected individuals.16,36 As a potential explanation of this, Kirk et al. 
reported a higher proportion of smoking among HIV infected people.37 This behavior combined 
with an immunosuppressed condition increased the relative risk of lung cancer 3.6 times among 








 A cumulative exposure of carcinogens from ambient outdoor air pollution, such as 
polycyclic aromatic hydrocarbon compound from fossil fuel, may cause inflammation in the 
respiratory system.25 In urban or industrialized settings, a significant increase in lung cancer risk 
has been reported due to increased fine particle concentration from engine emissions.38,39 Indoor 
air contamination resulting from cooking combustion and space heating also has been reported by 
studies, thereby increasing the risk of lung cancer.16,17 
Age at Diagnosis 
 Diagnosis of lung cancer is common among individuals ages 65–74 years.12 Currently, 
the median age at diagnosis of lung cancer in the US is 70 years.12 Data from 22 population-based 
central cancer registries in the US over the period of 1995–1999 showed that lung cancer was 
among the five most common cancers, with a significant increase in the younger age group, 
particularly people aged 40–49 years.40 Population-based data has reported around 10% of cases 
were diagnosed before age 55 years,12 while facility-based studies reported 12–14% of lung 
cancer cases occurred before age 50 years.41-43 The literature suggests that the changes to the 
median age at diagnosis in lung cancer cases of over 20 years earlier were associated with the 
smoking epidemic among the young people.17,23,44 
 Previous studies that used the cutoff age at diagnosis as 40–50 years to define younger-
onset cases reported differences in patient and tumor characteristics between younger- and older-
onset patients. Those diagnosed at less than 50 years of age had higher proportions of advanced 









 The association between gender and risk of lung cancer is closely related to cigarette 
smoking.17,23 Although smoking prevalence was higher among men than women in the 1940s,18 
after 1950 there was an increase in cigarette smoking among women, leading to the increased 
incidence of lung cancer in women.17,18 Studies reviewed by Cruz et al. suggest gender 
differences in the risk of lung cancer, indicating that a higher susceptibility among women may 
be due to differences in nicotine metabolism, metabolic activation of lung carcinogens, and 
hormonal factors between men and women.17  
 
Diagnosis of Lung Cancer 
 Lung cancer evaluation aims to efficiently and accurately establish the diagnosis and 
initial extent of the disease. The procedures include a check on medical history and physical 
examinations, followed by imaging tests and tests to obtain tissue diagnosis and measurement on 
the extent of disease.3  
 Smoking history, concurrent chronic obstructive pulmonary disease, and previous 
exposures to certain environmental and occupational carcinogens are obtained from the patient as 
part of individual medical history.3 In physical examinations, the patient’s general appearance 
may be normal or may show signs, such as lethargy, pallor, jaundice, or other significant 
comorbidities.3 Respiratory examinations may reveal issues with different areas. For example, 
tachypnea (abnormally rapid breathing) may indicate pleural effusion, post-obstructive 
pneumonia, or rib metastases; neck palpation may indicate that the cancer has spread to 
supraclavicular lymph nodes; and bronchial breath sounds and increased fremitus indicate 





 The subsequent examination may utilize imaging procedures, including chest radiograph, 
computed tomography (CT) and magnetic resonance imaging (MRI). Posteroanterior and lateral 
chest radiograph is usually the first standard test to detect bronchogenic carcinoma.3,51 The 
procedure also helps to assess the intrathoracic extent of the cancer, suggest subsequent work-up, 
and identify other thoracic disease. The literature suggests a wide spectrum of findings from this 
procedure, including a localized opacity (nodule or mass), pleural effusion, atelectasis, 
adenopathy, and possible histologic type of lung cancer.3 A CT procedure has been suggested to 
greatly enhance the imaging of bronchogenic carcinoma.17,51 The procedure can further define the 
primary lesion’s appearance, detect simultaneous parenchymal or pleural disease, display 
lymphangitic spread of malignancy, guide diagnostic maneuvers, and evaluate lymph nodes 
metastases.3 In lung cancer evaluation, an MRI is not a routine procedure, although it can detect 
vascular invasion better than a CT procedure.3  
 The accurate tissue diagnosis is important, not only to establish lung cancer diagnosis but 
also to develop a treatment plan. In most patients suspected of lung cancer, biopsy procedures are 
necessary because the clinical and radiographic procedures may not determine small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC).3 The common techniques used to obtain 
tissue for cytologic and histopathologic analysis are sputum examinations, flexible fiberoptic 
bronchoscopy, transthoracic needle aspiration, endoscopic ultrasound, and thoracic surgery.3  
 
Treatment of Lung Cancer 
 The treatment plan for lung cancer cases is defined mostly based on the type and stage of 
cancer.13 The majority of recommendations are made for NSCLC and SCLC,13,24 which comprise 






Non-small Cell Lung Cancer 
 For early-stage cancer (stages I and II) that is operable, surgery and resection are utilized 
as the primary treatment to provide increased longevity.24,52 A complete surgical resection, 
including lobectomy or complete lymph node dissection, should be conducted, particularly when 
smaller tumors (< 1–2cm) are identified.53 For patients with inoperable tumors, the options to 
consider would include radiotherapy and/or chemotherapy.13,24,52 Durable results, including 
reduction of toxicity and increase of five-year survival up to 40%, have been reported among 
medically inoperable patients treated with advanced radiotherapy methods.53 Promising evidence 
have been reported in the management of early-stage lung cancer, however, data from clinical 
observations and cancer registries suggest that the majority (more than 70%) of lung cancer cases 
are diagnosed at an advanced stage (stages III and IV).13  
 Lung cancer cases with operable stage III may receive multimodality therapy as a 
standard treatment, such as surgery followed by chemotherapy.24,53 For inoperable stage III, the 
treatment recommendation may include a sequential or concurrent combination of chemotherapy 
and radiotherapy or external radiation alone.24,52 As cancer progresses to advanced stages, such as 
stage IV, treatment options might include a combination of chemotherapy, palliative radiation, 
and targeted therapy.13,52 Other factors, such as comorbidities, performance status, and genetic 
factors, are considered for treatment recommendations.53  
Small Cell Lung Cancer 
 Although small percentages of lung cancer cases are classified as SCLC (13–15%), the 
disease has specific treatment recommendations as it is considered to be more aggressive and 
often at wide dissemination at the time of diagnosis than NSCLC.24,54 Treatment for SCLC is 
defined according to disease stage, general health, and existing comorbidities.24,53 The most 





radiation or chemotherapy alone; for extensive stage SCLC, the treatment recommendation 
includes the combination of chemotherapy regimens or chemotherapy alone.55,56 
 
Staging of Lung Cancer 
 Cancer staging describes the occurrence or spread of cancer at diagnosis, which is 
essential in the diagnosis process and development of the treatment plan for lung cancer patients. 
Cancer staging may help clinicians to identify the appropriate treatment plan, understand disease 
prognosis, evaluate treatment results, etc.13,24,25 The TNM system is the standard International 
Staging System for lung cancer administered by the Union for International Cancer Control.13,57 
The T category defines the size and extent of the primary tumor, the N category defines the 
absence or presence of regional lymph node involvement, and the M category defines the extent 
of distant metastases.13,24 The tumor stage system used in cancer registries was based on TNM 
staging in defining the categories of local stage (cancer confined to the organ of origin), regional 
stage (cancer spread to nearby tissues or lymph nodes in the area of the organ of origin), and 
distant stage (cancer spread to distant organs or parts of the body).11,13,57  
 In clinical practice and specific cancer registry, the TNM subsets with similar prognosis 
and treatment option are combined into different stage groups. For NSCLC, the assigned stages 
are 0, I, II, III, or IV; stage 0 is described as an in situ stage and the following stages are invasive 
cancer.13,24,25 Stage I represents the early-stage invasive cancer, while stage IV represents the 
most advanced stage. For SCLC, the combined staging group as applied in NSCLC is considered 
irrelevant. The International Association for the Study of Lung Cancer (IASLC) recommends 
different grouping of TNM staging system for SCLC by combining stages I–III into limited stage 
(LS) and renaming stage IV as the extensive stage (ES).56,58 The limited stage (LS-SCLC) is 





lymph nodes, while the extensive stage (ES-SCLC) is defined as cancer that has spread beyond 
the supraclavicular areas.24,56,58 
 
Figure 1. 1 The Schematic Illustration of Non-Small Cell Lung Cancer Staging. 
Originally presented in Lemjabbar-Alaoui H, et al. (2015). “Lung cancer: Biology and treatment 
options.” Biochim Biophys Acta. 2015;1856(2):189-210.24 Reprinted with permission. 
 
 
Histopathology of Lung Cancer 
 The international standard for histologic classification of lung tumors proposed by the 
WHO and the IASLC includes major histologic types of lung cancer, such as adenocarcinomas, 
squamous cell carcinomas, large cell carcinomas, and small cell carcinomas (SCLC).59 These 
major types can be classified into many other subtypes based on the different clinical significance 
of the tumor.59,60 The two most common histologic types are non-small cell lung cancer (NSCLC) 
and SCLC; their proportions of all lung cancer cases are approximately 80–83% and 10–13%, 
respectively.11,12 Studies suggest these histologic types have differences in etiology, pathology, 





 Of the NSCLC, adenocarcinoma accounts for approximately 40–45%12,61 and is 
commonly found in peripheral parts of the lung.16,24 Adenocarcinoma occurs mainly in current or 
former smokers, but is also the most common type of lung cancer seen in nonsmokers.62,63 In 
addition, adenocarcinomas are more likely to occur in younger people than other types of lung 
cancer.31,49 The second most common histologic type of NSCLC is squamous cell carcinomas, 
which accounts for 25–30% of cases.12,61 This subtype is often linked to a history of smoking and 
tends to be found in the central part of the lungs, near a major airway (bronchus).23,64,65  
 The SCLC tends to arise in the central mediastinum of the lung.56 Compared with 
NSCLC, the SCLC is extremely aggressive and spreads rapidly to nearby tissues or lymph nodes 
in the area of the organ of origin and is strongly associated with tobacco smoking.24,55,66 The 
SCLC is a malignant epithelial tumor consisting of small cells with scant cytoplasm, ill-defined 
cell borders, finely granular nuclear chromatin, and absent or inconspicuous nucleoli.67 
 
Survival of Lung Cancer Patients 
 Analyses of lung cancer data from multiple countries indicate that lung cancer patients 
had poor survivals; the five-year relative survival were 6–14% among men and 7–18% among 
women.6 In developing and less developed countries the number was even lower; the five-year 
relative survival of lung cancer cases was approximately around 9%.4,6 In the US, despite the 
achievements in lung cancer care in previous years, improvements in the five-year survival of 
lung cancer is low. A recent report indicates in four decades the absolute improvement of five-
year relative survival of lung cancer was only 6.5%; the five-year relative survival reported in 
1975 and 2012 were 12.2% and 18.7%, respectively.68  
 The low survival rate of lung cancer patients has been reported to be associated greatly 





of lung cancer symptoms, the majority of lung cancer cases were diagnosed at advanced 
stages,69,70 whereas available treatment options are most effective in early-stage cancer.13,25 
Studies have suggested many other factors that affect the survival of lung cancer patients, 
including patient characteristics such as age, gender, and race;41,71-73 smoking and smoking-
related comorbidities;74-77 treatment factors and socioeconomic factors.7,48,78-84  
 Tumor biology and hormonal factors were suggested in studies to explain gender-related 
differences in the survival of lung cancer patients.73,85 The estrogen mechanism, capacity to repair 
DNA damage, and PAH metabolism are some factors that differ between women and men.2 A 
possible explanation for the effect of age is that young patients may have a better health condition 
due to fewer comorbidities, which subsequently allows them to receive more aggressive treatment 
and benefit the survival.41,45,46 However, studies also suggest that young lung cancer patients may 
have a different character of disease that resulted in a worse prognosis. More of the young lung 
cancer patients were diagnosed at an advanced stage; young lung cancer cases also were 
suggested to have a different histologic type compared with older cases, which may indicate 
genetic variation.45,48,86,87  
 The histologic type and stage of cancer may explain differences associated with 
treatment. The NSCLC types of cancer are considered less aggressive,24 and with the available 
treatment options the five-year relative survival of NSCLC was 23%; the survival of early-stage 
cases was 60% and advanced stage cases was 5%.12 Whereas, for SCLC that has aggressive 
growth and wide infiltration, a recent data suggest the five-year survival of SCLC cases was only 
6.3%.12 The survival of SCLC has not significantly changed since the early 1990s.12 A meta-
analysis study suggests that due to the toxicity associated with chemoradiation, the survival 
benefit from treatment of LS-SCLC was limited to younger patients.88 Whereas findings from 






Treatment Refusal by Lung Cancer Patients 
 Patients with advanced chronic disease, such as lung cancer, are challenged with potential 
trade-offs between treatment benefits and burdens. For example, a study by Fried et al. indicated 
that for a low-burden treatment with restoration of current health, 98.7% of patients agreed to the 
treatment; however, when the outcome was survival but at the same time having severe functional 
impairment or cognitive impairment, more than 75% of patients decided to refuse the treatment.91 
Rothman et al. suggested that high proportions of treatment refusal may indicate insufficient 
patient-centered decision-making.92 Patients were more likely to refuse treatments that do not 
meet their treatment goal, as also suggested in studies reviewed by Puts et al.93 Many factors 
influence a patient’s decision to receive or forgo the recommended treatment. It may range from 
individual factors (such as age, gender, and race) to culture, the burden of treatment (such as 
length of hospital stay), extent of diagnostic procedures, invasive interventions, and the likelihood 
of the outcome.91,94 
 A review of cancer studies by Ward et al. suggests that compared with other cancers, 
lung cancer patients have higher rates of treatment refusal.95 The decline of recommended cancer 
treatment was not only associated with poor survival but also higher mortality risk.63,96 In 
addition, studies have suggested that age is one of the important factors that greatly influence a 
cancer patient’s decision regarding treatment.94,97 Older lung cancer patients were more likely to 
forgo treatment than their younger counterparts. Studies among early-stage NSCLC patients 
reported a positive association between the increase of age and refusal of recommended surgical 
treatment.98,99 However, due to data limitation, the studies were conducted only among early-
stage lung cancer cases 98,99 or older lung cancer cases.98 Not including advanced stage in the 






 In terms of gender differences, studies reveal that women with lung cancer more likely 
believed the disease to be incurable and that the treatment was only for comfort care.100,101 In 
addition, limited access to cancer care due to lack of medical insurance is another factor 
suggested by many studies to be associated with higher treatment refusal.95,102 Previous studies 
indicate that the risk of being uninsured varies by age; young lung cancer patients were more 
likely to be uninsured or underinsured as compared with their older counterparts 102,103 
 
Limitations of Previous Research 
 Previous studies conducted to estimate the prognosis of lung cancer patients indicate that 
many factors predict survival, including age at diagnosis. The inconclusive findings regarding 
whether the diagnosis of lung cancer at a younger age benefits survival suggested the need to 
examine the characteristics of younger-onset lung cancer cases and determine its difference with 
older-onset cases, as well as investigate the survival of these groups. In addition, many studies 
used simplify age category that was not represented younger-onset lung cancer. 
 Other studies have suggested that patient acceptance of recommended treatment is 
another essential factor in survival and an important point to reduce lung cancer mortality.12,63,104 
However, many of previous studies examined treatment refusal among early-stage cancer, or 
limited their study population to those recommended for surgery in a single-site hospital, or 
included small number of cases in the analysis. These restrictions may not allow a representative 
estimate of treatment refusal among lung cancer cases because a higher proportion of lung cancer 
diagnosed at advanced stages and more treatment refusal are anticipated from them. 
 In addition to gaps in the literature regarding survival of the young-onset lung cancer 
patients, studies suggested many of the young lung cancer patients having issues with access to 





opportunity to examine survival of patients who have similar access to cancer care and included 
information such smoking history, family history, and chemotherapy, that are limited in other 
databases.  
 To better describe the patient characteristics and have robust analyses, we used different 
categories of age at diagnosis to address the younger-onset cases and included a larger sample of 
lung cancer cases. Firstly, our analyses examined the characteristics of lung cancer patients 
diagnosed at different categories of age and examined their survival. At the same time, we 
investigated factors associated with survival, including age at diagnosis and treatment refusal. 
Secondly, our analyses investigated factors associated with treatment refusal by patients. We used 
two large cancer databases for our analyses; the National Cancer Database (NCDB), which 
represents the general population, and the VACCR, which represents a unique veteran population. 
 
Specific Aims 
 The burden of morbidity and mortality caused by lung cancer cases emphasize the urgent 
need to conduct more studies to suggest improvement in cancer care. The overall objective of this 
dissertation was to investigate survival and treatment refusal of lung cancer patients. We 
established three specific aims to address the study objective.  
Specific aim 1: To describe the characteristics and examine survival of NSCLC patients by 
age at diagnosis  
Specific aim 2: To investigate factors associated with treatment refusal and the impact of 
treatment refusal on the survival of SCLC patients  
Specific aim 3: To investigate factors associated with treatment refusal by NSCLC patients  






National Cancer Database 
 The NCDB provides a clinical oncology database of hospital registry data collected from 
more than 1,500 Commission on Cancer (CoC)-accredited facilities.107-109 The database included 
cancer cases diagnosed and or treated at the CoC-accredited facilities. It supports data for national 
cancer surveillance and resource for cancer quality improvement through a joint program of the 
American College of Surgeons and the ACS.110 The database captures approximately 70% of 
newly diagnosed cancer cases nationwide and more than 34 million records with detailed 
information, including patient and tumor characteristics, treatments, and outcome.111,112 
Veterans Affairs Central Cancer Registry 
 The VACCR serves a shared comprehensive cancer database of the US veterans 
population from Veterans Affairs medical centers facilities.113,114 The Veteran Affairs provides an 
integrated health care system access for veterans in a single payer system.114,115 The VACCR uses 
standards established by institutions including the American College of Surgeons Commission on 
Cancer, the American Joint Commission on Cancer, and the North American Association of 
Central Cancer Registries, among others.113 Data in VACCR, include extensive demographics, 
cancer identification, the extent of disease and staging, first course of treatment, and outcomes.113 
 
Conceptual Framework  
 In this dissertation, we adapted the model on measures of patient-centered cancer 
outcomes research using observational data by Carpenter et al.116 The model emphasizes the 
expanding repositories of secondary data, such as cancer registry, and electronic health records, 





model as a baseline, we identified measures and outcomes from variables in cancer registries that 
are relevant to our study objectives.  
 Figure 1.2 exhibits multiple factors relevant to factors associated with the survival of lung 
cancer care. One important factor that we added in the model is treatment acceptance as 
intermediate outcome. We view this model as a longitudinal process. For example, the 
improvement in lung cancer care will eventually increase patient’s survival. However, prior to 
evaluate the survival it is important to see the acceptance towards treatment. 
 Many of the variables listed in the model are not available for inclusion in our analyses; 
however, it is helpful for future studies to include and adjust multiple factors, not only for cancer 
care evaluation but also to address challenges in the interpretation of findings from previous 
studies. Our analyses have included most components in the model, i.e., patient demographics 
(age, gender, family history of cancer, race, category of residence, composite comorbidity, 
primary payer/insurance status), provider characteristics (cancer care facility), cancer 
characteristics (stage, histology), treatment (surgery, chemotherapy, radiation, and combined 
therapies), intermediate outcome (treatment acceptance), and outcome (survival), these variables 
are marked in the model. Taking into account various components in our analyses ensured the 













SURVIVAL OF NON-SMALL CELL LUNG CANCER PATIENTS  
IN THE UNITED STATES VETERANS AFFAIRS POPULATION BY AGE  
 
Abstract 
Background: A significant number of young cases of non-small cell lung cancer (NSCLC) has 
been reported. This study compared the characteristics of younger-onset cases to older 
counterparts and examined their survival. Methods: We analyzed data from the Veterans Affairs 
Central Cancer Registry (VACCR) from 2001–2008. We estimated survival probability using the 
Kaplan–Meier method and compared survival of different age categories using Cox Proportional 
Hazards regression analysis. Results: Of the 48,899 NSCLC cases studied, 1,182 patients were 
diagnosed as younger-onset (< 50 years). The younger-onset group had high proportions of 
advanced stage at diagnosis, current smokers, positive family history of cancer, and 
adenocarcinoma histology. The five-year survival of younger-onset patients was 5.6% compared 
with 3.0% of older-onset patients (> 70 years). Of those with early-stage (I and II), younger-onset 
patients had a lower risk of mortality than intermediate-onset (50–70 years) (hazard ratio [HR] = 
0.78; 95% CI: 0.62–0.98); the intermediate-onset patients had a lower risk than older-onset (HR = 
0.66; 95% CI: 0.62–0.69). For advanced stage (III and IV), there was no difference in mortality 
risk between younger- and intermediate-onset patients, whereas those with older-onset had a 24% 
increased risk of mortality than intermediate-onset patients (HR = 1.24; 95% CI: 1.20-1.28). 
Conclusions: Younger-onset NSCLC patients have a better five-year survival than older-onset 
patients, although more of them were diagnosed at an advanced stage. Further investigations in 
genetic or tumor molecular are recommended as younger-onset patients present with more 






 In the US, lung cancer is the leading cause of cancer-related death, with an estimated 
154,050 deaths in 2018.12 Of lung cancer subtypes, NSCLC accounts for 84% of the cases.12 
Historically, lung cancer has been predominately diagnosed among the older population, with a 
median age at diagnosis of 70 years. However, recent studies have reported a substantial 
proportion of patients developed NSCLC at younger age.12,40,44,45  
 Patients with younger-onset NSCLC, age at diagnosis between 40 and 50 years, have 
been reported to have distinct characteristics such as advanced stage at diagnosis,44-46 high 
proportion of adenocarcinoma histologic subtype,47,48 and predisposing genetic factors33,49,50 in 
comparison  to older-onset patients. Previous studies have reported higher proportions of tobacco 
use, a better performance status, and more aggressive treatment in younger-onset patients.41,45,46 
These factors have been suggested as contributing factors for the different prognoses between 
younger and older-onset NSCLC patients. 
 In previous studies, the influence of age at diagnosis on patient survival of NSCLC 
patients has been found to be inconclusive. Studies conducted using different cancer registries, 
i.e., Surveillance Epidemiology and End Results (SEER) and NCDB, have reported that young 
patients tend to have less comorbidity and better performance status, which enable them to 
receive more comprehensive treatment and results in better survival.45,47,79 Findings from a study 
by Mauri et al. indicate no difference in overall survival between patients age < 45 and > 45 
years.117 A hospital-based study by Bryant et al. indicated that younger NSCLC patients have a 
significantly worse prognosis than older patients due to the aggressiveness of different cancer 
types among the younger patients.48 Other than cancer aggressiveness, poorer survival among the 
younger patients appeared to be related to limited access to and use of care among younger 
patients. Insurance is a contributing factor related to issues in access to cancer care. Studies have 





delay in cancer diagnosis.103,105 Findings from studies also indicate that younger patients often 
delayed visiting health care providers until they became symptomatic and thus were diagnosed at 
a more advanced stage.42,43,48,86,118 Therefore, using a large cohort of patients, such as VA patients 
who have similar access to cancer care, would allow the evaluation for effect of age at diagnosis 
on patient survival. 
 The purpose of this study was to describe the characteristics of younger-onset NSCLC 
cases and to examine the survival based on age at diagnosis of patients treated within the VA 
health care system, which provides a more equitable access to health care. 
 
Materials and Methods 
Study Population, Design, and Data Source 
 The Veterans Affairs (VA) facilities maintain a shared comprehensive cancer database 
that covers 132 Veterans Affairs medical centers. In addition, the VACCR contains demographic 
and clinical information of cancer patients who have been diagnosed and/or treated at the VA 
medical centers.113 The VACCR uses standards established by institutions including the 
American College of Surgeons Commission on Cancer, the American Joint Commission on 
Cancer, and the North American Association of Central Cancer Registries.113 
 In this retrospective cohort study, we analyzed data of patients with NSCLC of all 
histology subtypes included in the VACCR database between 2001 and 2008. Analyses were 
conducted utilizing data of those patients diagnosed with a primary invasive lung cancer with a 







Exposures and Outcomes  
 We included data on patient age at diagnosis, race, gender, smoking history, family 
history of cancer, alcohol history, stage at diagnosis, histology type, and treatment received as 
predictor variables. The five-year overall mortality, the study outcome, was defined as the time 
from diagnosis of NSCLC to (a) the date of death (from any cause), (b) loss to follow-up, or (c) 
vital status up to 60 months (after diagnosis), whichever came first. Age at diagnosis of NSCLC 
was categorized as younger-onset (diagnosed before age 50 years), intermediate-onset (diagnosed 
at age 50–70 years), and older-onset (diagnosed at 70 years and after).  
Statistical Analysis 
 We used the chi-square test to compare patient characteristics, the Kaplan–Meier method 
to estimate survival probabilities, and the log-rank test to assess survival differences. 
Multivariable Cox Proportional Hazards (PH) regression was performed to examine the 
association between age at diagnosis and overall survival, adjusting for other factors including 
smoking history, alcohol history, family history of cancer, clinical stage, and histology subtypes. 
The assumption of proportional hazards was tested using the log–log plots. Covariates with p-
value > 0.25 were excluded in the final model. All data were analyzed using the SAS software 
version 9.4 (SAS Institute; Cary, NC). 
Confidentiality and Ethics 
 The study used data from a de-identified VACCR database and was approved by the 
Institutional Review Board at the VA-Nebraska Western Iowa Health Care System. The views 
expressed in this publication are solely those of the authors, including the statements made in the 
discussion and conclusions drawn from the data. The VA has not verified, and is not responsible 







Demographic and Clinical Characteristics 
 Analyses included 48,899 NSCLC cases recorded in the VA database between 2001 and 
2008. Of these 1,182 patients were diagnosed as younger-onset lung cancer. Comparison of 
patient demographic and clinical characteristics by age categories are presented in Table 2.1. 
 Younger-onset patients were more likely to be diagnosed at an advanced stage (stages III 
and IV) than the older groups. A higher proportion of adenocarcinoma was present among the 
younger-onset patients, whereas more squamous cell carcinoma was observed among the older-
onset patients. Higher proportions of younger-onset patients received combined cancer treatment 
than either of the intermediate-onset and older-onset patients.  
 We used family history of cancer as a surrogate of inherent factors for lung cancer in our 
analyses. A higher proportion of younger-onset patients had a positive family history of cancer 
(39%) than older-onset patients (30%). The proportion of current smokers was higher among the 
younger-onset patients (76%) in comparison to the intermediate-onset (62%), and older-onset 
patients (37%) as shown in Table 2.1. 
The Survival of NSCLC Cases 
 The younger-onset cohort had better median survival than older-onset patients (9 versus 7 
months) as shown in Table 2.2. The five-year survival of patients diagnosed at the three age 
categories was significantly different (log-rank p < 0.001). A higher proportion of younger-onset 
patients (6%) survived to 60 months after diagnosis than intermediate-onset (5%) and older-onset 
(3%) patients.  
 The log–log tests indicated all predictors met the proportional hazards (PH) assumption. 
Therefore, we included age at diagnosis, smoking history, alcohol history, family history of 





stratified by stage in Table 2.3 and indicated that among early-stage (stages I and II), younger-
onset patients had a 22% lower risk of mortality than intermediate-onset patients (HR = 0.78; 
95% CI: 0.62–0.98). No difference was found in the comparison of mortality risk between 
younger-onset and intermediate-onset patients among those with advanced stage; however, older-




 Our study results show that in the veteran population with NSCLC, overall survival is 
affected by various factors, including age at diagnosis, smoking history, alcohol history, family 
history of cancer, clinical stage at diagnosis, and histology. Of these factors, age at diagnosis and 
cancer stage are factors that strongly influence patient survival. Younger-onset NSCLC patients 
had a better five-year survival than patients diagnosed at an older age. Mortality risk stratified by 
cancer stage showed consistent patterns. The younger-onset lung cancer patients had a lower 
mortality risk than intermediate-onset, particularly among early-stage. Similarly, intermediate-
onset patients also showed a lower risk of death than those with older-onset in both early and 
advanced stages of NSCLC.  
 As lung cancer has been widely regarded as a disease affecting older people, it is likely 
that younger people may pay less attention to respiratory symptoms and may not think that they 
could have developed NSCLC at a younger than typical age. In fact, some studies have suggested 
that younger people’s decreased attention to their health leads to lower proportions of cancer 
screening, causing them to be symptomatic at the time of presentation.41,119 Our findings were 
corroborated previous studies that observed more of the younger-onset patient diagnosed with 





more aggressive among the young, which may be another reason the younger-onset group is 
frequently found at a more advanced stage.48  
 Overall survival of patients diagnosed at different age categories in the multivariable 
analyses showed that younger-onset patients had a lower risk of mortality than the older patients. 
Similar findings have been reported by previous studies suggesting lower mortality risk among 
younger-onset across cancer stages at diagnosis.45,47,79 One posited explanation of this has been 
that younger-onset patients may have fewer comorbidities and are more likely to receive 
aggressive treatment than older counterparts.41,46,71 Our analyses indicated that among the 
veterans population, that received equal access to health care, those with younger-onset had less 
mortality risk compared with those diagnosed in older groups, particularly among early-stage. 
One possible explanation is that the disease aggressiveness in advanced stages of NSCLC reduces 
the observed survival benefits in those with younger-onset. 
 An interesting finding in our analysis was the higher proportion of adenocarcinoma in 
younger patients, despite the high proportion of current smokers. Of all histologic subtypes, 
adenocarcinoma seems to have the least association with smoking, and is the most common 
subtype of lung cancer in never and light smokers.63 Given the high proportion of a family history 
of cancer in the younger-onset cohort, it is likely that in a setting of increased susceptibility, a less 
cumulative smoking exposure may be needed to cause lung adenocarcinoma at a younger age. 
Moreover, the possibility of other exposures among the veteran population, such as asbestos and 
other chemicals components, could explain the increased risk of cancer among young adults.120 
 A strength of the present study was the ability to analyze smoking status among cancer 
patients, a variable that is not available in most of the cancer registries such as SEER and NCDB. 
In addition, the VA population has been known to have a higher proportion of smokers than the 
general population.120,121 The increased proportion of NSCLC cases among the younger-onset 





cigarettes smoked, total pack-years, and age at smoking initiation.122 Our findings among the 
veterans population were in agreement with previous studies42,43 and demonstrated a higher 
proportion of current smokers among younger-onset patients. Bhat et al. suggested that current 
smokers were more likely to be diagnosed with NSCLC at a younger age.62  
  Our results also demonstrated that a higher proportion of younger-onset patients had a 
positive family history of cancer. This corroborates findings in other studies that have shown a 
positive association between genetic and NSCLC, especially among the younger-onset 
patients.32,35,49,50 It appears that inherited risk factors in combination with tobacco smoking 
increases the risk of diagnosis with the disease at a younger age.33,49,50 Our study showed that the 
median survival of patients with a positive family history of cancer was higher than those 
without.  
 Other studies among NSCLC patients in the veterans population have suggested similar 
findings, in that patients with a positive family history of cancer have a lower risk of mortality 
than those without.62,123 This is possibly due to increased awareness among patients with a 
positive family history, which leads to earlier lung cancer screening. In addition, because of 
concern about military exposures and the accessible health care services provided by the VA 
health care system, more veterans may be screened for lung cancer120 leading to earlier diagnosis 
and receipt of prompt treatment resulting in better survival.  
 We have found no study addressed the issue of survival among different age at diagnosis 
of NSCLC patients in the veteran population. The VACCR provided us with a large national 
cancer database of veterans in the US, with equal access to care and comprehensive medical 
insurance benefits available to all enrolled veterans.124 In addition, the database included 
information on smoking history, family history of cancer, and treatment received including 
chemotherapy, which is frequently stated as a limitation in previous studies using cancer registry 





demonstrate important findings on factors associated with survival of NSCLC patients, 
particularly among younger-onset NSCLC patients in the US veterans population.  
 Nevertheless, we acknowledge the following limitations in our study. First, we were 
unable to explain the variation in patient performance status and comorbidity on patient survival 
as the database we utilized did not capture this information. A study by De Rijke et al. suggests 
these two factors are important predictors of mortality and are correlated with increases in patient 
age.125 Second, due to the characteristics of the veterans population, these findings may not be 
generalizable to other cohorts. Studies have reported a higher proportion of female patients 
among younger-onset,45,47,79 however, most of the patients in our study were male, thus we could 
not explain variation according to gender. Nevertheless, it is unlikely that either of these factors 
would have detracted the interpretation of the present study results.  
 
Conclusions 
 Younger-onset NSCLC patients have a better five-year survival than older-onset patients. 
The lower mortality risk observed in younger-onset NSCLC might indicate an area of 
improvements such as better access to cancer screening and cancer care, and recommendations on 
the use of aggressive treatments that will result in better patient survival. In addition, with more 
younger-onset patients presenting with advanced stage cancer, adenocarcinoma, and positive 
family history of cancer, further investigations into genetic or tumor molecular characteristics are 
needed. These will help to understand the associations between genetic susceptibility, 
environmental carcinogens including tobacco smoking, and treatment-specific factors on survival 







Table 2. 1 Characteristics of Non-Small Cell Lung Cancer Patients by Age (N=48,899)  
Characteristics 
<50 years 
(n = 1,182) 
50–70 years 
(n = 26,787) 
>70 years 
(n = 20,930) p  value n % n % n % 
Gender        
Female 101 8.54 528 1.97 240 1.15 < 0.001 Male 1,081 91.46 26,259 98.03 20,690 98.85 
Race        
White 779 65.91 21,478 80.18 17,168 82.03 
< 0.001 Black  371 31.39 4,702 17.55 3,304 15.79 
Others/unknown 32 2.71 607 2.27 458 2.19 
Smoking History        
Never smokers 40 3.38 659 2.46 907 4.33 
< 0.001 Former smokers 149 12.61 7,618 28.44 10,438 49.87 Current smokers 893 75.55 16,635 62.17 7,754 37.05 
Unknown 100 8.46 1,857 6.93 1,831 8.75 
Alcohol History        
Never  223 18.87 6,244 23.31 6,619 31.62 
< 0.001 Former  239 20.22 6,296 23.50 4,916 23.49 Current  540 45.69 10,015 37.39 5,283 25.24 
Unknown 180 15.23 4,232 15.80 4,112 19.65 
Family History of Cancer        
No 413 34.94 9,727 36.31 8,210 39.23 
< 0.001 Yes 460 38.92 9,960 37.18 6,249 29.86 
Unknown 309 26.14 7,100 26.51 6,471 30.92 
Clinical Stage (AJCC)        
I and II 283 23.94 7,965 29.73 6,902 32.98 
< 0.001 III 358 30.29 7,426 27.72 5,790 27.66 
IV 541 45.77 11,396 42.54 8,238 39.36 
Histology        
Adenocarcinoma  456 38.58 8,927 33.33 5,784 27.63 
< 0.001 
Squamous cell carcinoma 290 24.53 8,877 33.14 7,248 34.63 
Large cell carcinoma 53 4.48 870 3.25 518 2.47 
NSCLC, NOS 282 23.86 5,766 21.53 4,284 20.47 
Others  101 8.54 2,347 8.76 3,096 14.79 
Type of Treatment         
Chemotherapy only 160 13.54 3,662 13.67 2,278 10.88 
< 0.001 
Radiation only 167 14.13 4,170 15.57 4,101 19.59 
Surgery only 170 14.38 4,840 18.07 3,244 15.50 
Chemoradiation 347 29.36 5,628 21.01 2,210 10.56 
Surgery with chemotherapy with or 
without radiation 
128 10.83 2,135 7.97 679 3.24 
No surgery or radiation or 
chemotherapy recorded/ 
unknown  
210 17.77 6,352 23.71 8,418 40.22 


















Age 50–70 years  26,787 9 5.0 < 0.001 
 < 50  1,182 9 5.6 
 > 70  20,922 7 3.0 
Gender Female 869 11 0.0 < 0.001 
 Male 48,022 8 4.1 
Race White 39,420 8 4.2 0.546 
 Black  8,374 8 3.7 
 Others/unknown 421 9 3.0 
Smoking History Never smokers 1,606 8 0.0 < 0.001 
 Former smokers 18,204 9 4.4 
 Current smokers 25,297 8 4.1 
Alcohol History Never  13,085 9 4.2 < 0.001 
 Former  11,450 8 3.1 
 Current  15,837 9 4.8 
Family History of Cancer  No 18,349 8 3.7 < 0.001 
 Yes 16,668 9 4.3 
Clinical Stage (AJCC) I and II 15,149 20 11.7 < 0.001 
 III 13,573 9 2.6 
 IV 20,169 4 0.5 
Histology Squamous cell carcinoma 16,411 10 4.9 < 0.001 
 Adenocarcinoma 15,165 10 5.8 
 Large cell carcinoma 1,441 8 4.2 
 NSCLC, NOS 10,331 7 1.8 
 Others  5,543 5 2.1 
Treatment No surgery or radiation or 
chemotherapy 
14,641 3 0.7 < 0.001 
 Chemotherapy only 6,099 9 1.0 
 Radiation only 8,437 5 1.1 
 Surgery only 8,253 28 18.7 
 Chemoradiation 8,184 11 2.8 
 Surgery with chemotherapy 
with or without radiation 
2,941 23 1.2 
NSCLC = non-small cell lung cancer; NOS = not otherwise specified 






Table 2. 3 Multivariable Cox Regression of Factors Associated with Survival of NSCLC Cases  
Characteristics 
Stage I and II  
Characteristics 
Stage III and IV 
AHR 95% CI p value  AHR 95% CI p value 
Age     Age    
50–70 years  Ref    50–70  Ref   
< 50  0.78 0.62-0.98 0.031  < 50  0.96 0.88-1.04 0.298 
> 70  1.52 1.44-1.61 < 0.001  > 70  1.24 1.20-1.28 < 0.001 
Smoking History     Smoking History    
Never smokers Ref    Never smokers Ref   
Former smokers 1.01 0.88-1.17 0.842  Former smokers 1.06 0.99-1.15 0.095 
Current smokers 1.14 0.99-1.31 0.069  Current smokers 1.12 1.04-1.21 0.002 
Alcohol History     Alcohol History    
Never  Ref    Never  Ref   
Former  1.11 1.04-1.19 0.002  Former  1.06 1.02-1.10 0.002 
Current  0.92 0.86-0.98 0.011  Current  0.98 0.95-1.01 0.252 
Family History      Family History     
No Ref    No Ref   
Yes 0.94 0.89-0.99 0.018  Yes 0.92 0.89-0.94 < 0.001 
Clinical Stage 
(AJCC)    
  Clinical Stage  
(AJCC)   
 
I Ref    III Ref   
II 1.49 1.40-1.58 < 0.001  IV 1.88 1.83-1.94 < 0.001 
Histology     Histology    
Squamous cell  Ref    Squamous cell  Ref   
Adenocarcinoma 0.78 0.73-0.83 < 0.001  Adenocarcinoma 1.02 0.99-1.06 0.225 
Large cell 1.04 .88-1.23 0.614  Large cell 1.14 1.05-1.24 0.002 
NSCLC, NOS 1.29 1.20-1.39 < 0.001  NSCLC, NOS 1.10 1.06-1.14 < 0.001 
Others  1.24 1.13-1.36 < 0.001  Others  1.40 1.33-1.47 < 0.001 
+ Gender, race and treatment were not included in the multivariable analysis 







FACTORS ASSOCIATED WITH TREATMENT REFUSAL  
AND IMPACT OF TREATMENT REFUSAL ON SURVIVAL OF  
SMALL CELL LUNG CANCER PATIENTS 
 
Abstract 
Background: With less than 7% of small cell lung cancer (SCLC) patients surviving five years 
after diagnosis, the receipt of recommended treatment is of utmost importance for patient 
survival. Nevertheless, treatment refusal of SCLC patients has not been studied well. Our study 
examined factors associated with treatment refusal and the effect of refusal on patient survival. 
Methods: We analyzed data of 107,988 SCLC patients diagnosed between 2003 and 2012 from 
the National Cancer Database. Treatment refusals were analyzed separately for 
chemoradiotherapy among limited stage (LS-SCLC) and chemotherapy among extensive stage 
(ES-SCLC) patients. We used logistic regression to investigate factors associated with treatment 
refusal. We estimated survival probability using the Kaplan–Meier method and compared 
survival of those who received and refused treatment using Cox Proportional Hazards regression 
analysis. Results: The refusals of chemoradiotherapy among LS-SCLC and chemotherapy among 
ES-SCLC patients were 1.34% and 4.70%, respectively. From 2003 to 2012, trends show an 
increase of refusals, especially among the ES-SCLC recommended chemotherapy. Multivariable 
analyses showed that in both SCLC groups, older age at diagnosis (> 70 years), female gender, 
uninsured status, and presence of comorbidities were associated with treatment refusals. LS-
SCLC patients who refused chemoradiotherapy had a higher risk of mortality than those who 
received treatment (hazard ratio [HR] = 4.96; 95% CI: 4.45–5.53); the median survival of those 





Similarly, ES-SCLC patients who refused chemotherapy had a higher risk of mortality than those 
who received treatment (HR = 3.69; 95% CI: 3.48–3.92); the median survival was 1 month versus 
7 months, respectively (p < 0.001). Conclusions: Treatment refusal among SCLC patients was 
associated with worse survival; therefore, strategies to increase patient acceptance of the 








 Of the estimated 234,030 new lung cancer cases diagnosed in the United States (US) in 
2018, more than 30,000 cases were identified as small cell lung cancer (SCLC).12 Analyses of the 
surveillance, epidemiology, and end results reported the five-year survival rate of SCLC was less 
than 7%.12 In addition, in the last two decades, the SCLC survival rate has shown little 
improvement.83  
 Therapeutic options for SCLC have not significantly changed within the last 30 
years.126,127 Concurrent chemoradiotherapy is typically recommended for patients diagnosed with 
limited stage (LS-SCLC); whereas those diagnosed with extensive stage (ES-SCLC) are 
predominantly treated with chemotherapy.55,126,128 Lack of patient acceptance of recommended 
treatment has been implicated by previous studies as a key factor in SCLC survival.126,127,129 
Nonetheless, there is a lack of research concerning treatment refusal among SCLC patients.127,130 
 Our study addressed this gap by examining factors associated with treatment refusal by 
SCLC patients from a US national facility-based cancer registry. We also analyzed the trend of 
treatment refusal over time as well as the effect of treatment refusal on patient survival.  
 
Materials and Methods 
Study Population, Design, and Data Source 
 The National Cancer Database (NCDB) provides national cancer surveillance data 
through a joint program of the Commission on Cancer (CoC) of the American College of 
Surgeons and the American Cancer Society (ACS).107 According to the United States Cancer 
Statistics, this database captures approximately 70% of newly diagnosed cancer cases.107,112 
 We used cross-sectional design in the analysis of factors associated with treatment refusal 





the 198,405 SCLC cases diagnosed between 2003 and 2012. Figure 4.1 shows the sample 
selection process. Criteria for data inclusion were: (1) confirmed diagnosis of primary invasive 
SCLC according to the International Classification of Disease for Oncology Third Edition (ICD-
O-3) codes 8041-8045, (2) diagnosis established at a CoC-accredited facility and patient received 
all or part of their treatment from CoC facility/facilities, (3) diagnosis confirmed with cancer 
stage and patient treated at one or more of the following types of CoC facilities: community, 
comprehensive community, and academic cancer programs, (4) known insurance status, and (5) 
recommendation for first-course of treatment was either chemotherapy or radiation or 
combination of chemoradiotherapy. We utilized the data of 107,988 eligible patients in our 
analyses. 
Exposures and Outcomes  
 We included sociodemographic and clinical characteristics as predictor variables. 
Information on cancer stage was taken from the NCDB analytic stage, which uses standards 
publicized by the American Joint Committee on Cancer (AJCC) 7th edition.107 In the analysis, we 
followed the recommendation of the IASLC by grouping stages I–III as limited stage (LS-SCLC) 
and stage IV as extensive stage (ES-SCLC).56 Comorbidity was recorded as Charlson/Deyo 
Comorbid Conditions (CDCC).111 We used the NCDB definition of median income quartile 
according to the proportion of income range in the patient’s area of residence for income 
categories. The category of residence is based on information established by the United States 
Department of Agriculture Economic Research Services.107 
 Our outcome variables were refusal of recommended treatment and five-year overall 
mortality. Refusal of recommended treatment was defined as standard therapies recommended by 
a physician(s) and refused by the patient. We analyzed data of those who were recommended 
chemoradiotherapy among LS-SCLC and chemotherapy among ES-SCLC patients. Our analysis 





through the comparison of their median survival to those who accepted recommended treatment. 
In addition, we examined the effect of treatment refusal on patient survival in the multivariable 
model. 
Statistical Analysis 
 The chi-square test was used to examine differences in demographic and clinical 
characteristics of patients with limited and extensive stages of SCLC who refused and received 
the recommended treatment. We used multivariable logistic regression to examine factors 
associated with refusal of chemoradiotherapy among patients with LS-SCLC and refusal of 
chemotherapy among patients with ES-SCLC. Backward selection was used to fit the 
multivariable logistic regression model. Changes in the proportion of treatment refusal over time 
for cases diagnosed between 2003 and 2012 are shown graphically in Figure 4.2. We used the 
Kaplan–Meier method to estimate survival probabilities and log-rank test to assess survival 
differences. We performed multivariable Cox Proportional Hazards (PH) regression to examine 
the effect of treatment refusal on the risk of mortality adjusted for other factors. The PH 
assumption was tested using the log–log plots; all predictors met the proportionality assumption. 
Analyses were performed using the SAS software version 9.4 (SAS Institute; Cary, NC).  
Confidentiality and Ethics 
 We used data from a de-identified NCDB file. The ACS and CoC have not verified, and 
neither is responsible for the analytic and statistical methods utilized in this study. The statements 
made in the discussion and the conclusions drawn from these data are solely the authors’ 
responsibility. This study has been classified as exempt by University of Nebraska Medical 







Demographic and Clinical Characteristics 
 Of the 107,988 SCLC cases included in the analysis, 40,432 cases were diagnosed with 
LS-SCLC and 67,556 cases with ES-SCLC. Comparison of characteristics of patients who 
received and refused treatment for LS-SCLC and ES-SCLC are presented in Table 3.1. Separate 
analyses among those LS-SCLC and ES-SCLC showed that a higher proportion of patients of 
older-onset age (> 70 years), female and treated at the comprehensive community cancer program 
refused the recommended treatment modalities (p < 0.001). Interestingly, those without 
comorbidity had a higher proportion of refusal than those with comorbidities.  
 For the first-course treatment (data not shown), of the LS-SCLC patients (n = 40,432) 
recommendation for chemoradiotherapy was given to 75% of the cases. Among patients 
diagnosed with ES-SCLC (n = 67,556), the majority of them were recommended either for 
chemotherapy (47%) or chemoradiotherapy (45%).  
The Trend of Treatment Refusal  
 In total, 1,898 cases declined the recommended chemoradiotherapy of LS-SCLC and the 
recommended chemotherapy of ES-SCLC. Figure 4.2 shows an increase in the proportion of 
refusal of each therapy over 10 years. Overall, refusal of the recommended chemoradiotherapy 
among patients diagnosed with LS-SCLC was 1.34% and refusal of the recommended 
chemotherapy among ES-SCLC patients was 4.7%. Analysis of 10 years’ worth of data shows 
that the increase in refusal among those with ES-SCLC was higher (50%) than it was among 
those with LS-SCLC (34%). 
Factors Associated with Treatment Refusal 
 After adjusting for demographic and clinical characteristics, we found that age at 





chemoradiotherapy among LS-SCLC patients (Table 3.2). Patients diagnosed at age > 70 years 
were more likely to refuse treatment than those aged 50–70 years; the adjusted odds ratio (AOR) 
for refusal of chemoradiotherapy was 3.50 (95% CI: 2.77–4.44). Women were more likely to 
refuse recommended chemoradiotherapy than men, AOR was 1.29 (95% CI: 1.05–1.58). 
Compared with those with private insurance, uninsured patients were more likely to refuse 
treatment (AOR = 3.61, 95% CI: 2.05–6.35). In addition, we found that patients with comorbid 
conditions were more likely to refuse recommended chemoradiotherapy than those without 
comorbidity, AOR was 2.54 (95% CI: 1.94–3.31). 
 The multivariable logistic regression analysis showed that similar factors, as those 
observed in the analysis of LS-SCLC, were associated with refusal of chemotherapy among ES-
SCLC patients (Table 3.2). Patients diagnosed at age > 70 years were more likely to refuse 
chemotherapy than those age 50–70 years (AOR = 2.25; 95% CI: 1.99–2.55). Women were more 
likely to refuse recommended treatment than men (AOR = 1.42; 95% CI: 1.27–1.58). Uninsured 
patients were more likely to refuse chemotherapy than those with private insurance (AOR = 1.76; 
95% CI: 1.29–2.40). ES-SCLC patients with comorbidities were more likely to refuse 
chemotherapy than patients without comorbidity, AOR was 1.43 (95% CI: 1.23–1.65). As 
previous studies had suggested,131,132 interactions of race with variables including gender, 
insurance status, and comorbidity were examined separately for both LS-SCLC and ES-SCLC, 
but no significant association was found.  
The Survival of SCLC Cases 
 The overall median survival for all SCLC patients included in the analysis was 9.4 
months. Among LS-SCLC patients who were recommended chemoradiotherapy, the median 
survival of patients who refused and received the treatment were 3 and 18 months, respectively (p 
< 0.001) (Figure 4.3). For ES-SCLC patients, median survival of those who refused 





0.001). Within one year following the diagnosis (data not shown) among LS-SCLC patients who 
were recommended chemoradiotherapy, 67% of patients who received the treatment had 
survived, compared with 14% of those who declined. The five-year survival of LS-SCLC patients 
who received chemoradiotherapy was 17% compared with only 2% of those who refused (Figure 
4.3). For ES-SCLC, the one-year survival of patients who received the recommended 
chemotherapy was 25%, compared with 3% of those who refused.  
 We included age, gender, primary payer, category of residence, presence of comorbidity, 
facility, and treatment status in multivariable analyses using Cox PH regression. Results are 
presented in Table 3.3 and indicate that among LS-SCLC patients recommended 
chemoradiotherapy, those who refused treatment had a higher risk of mortality than those who 
received treatment (hazard ratio [HR] = 4.96; 95% CI: 4.45–5.53). Similarly, among ES-SCLC 
patients who were recommended chemotherapy, patients who refused treatment had a higher risk 
of mortality than those who received (HR = 3.69; 95% CI: 3.48–3.92). 
 
Discussion 
 Our study found that the majority of first-course treatments received by SCLC patients in 
the database met national clinical practice guidelines, which include a combination of 
chemoradiotherapy for LS-SCLC and chemotherapy alone for ES-SCLC.55,133 Regarding survival 
among both LS-SCLC and ES-SCLC groups, patients who accepted recommended treatment had 
significantly higher survival than those who refused. The overall refusal of the recommended 
chemoradiotherapy among LS-SCLC patients was 1.34% and refusal of chemotherapy among 
ES-SCLC patients was 4.7%. These proportions are smaller than the overall treatment refusal 
reported by Ward et al., which was 9% from analysis of 11 cancer sites.95 Our analyses indicated 
that over time there were increases in the proportions of treatment refusal of both LS and ES-





increased by 50% in 10 years. The fact that three-fourths of SCLC cases are diagnosed with ES-
SCLC suggests that our findings on treatment refusal deserve special attention. Aizer et al. 
indicate that compared with other cancers, refusal of treatment among SCLC patients was more 
likely to result in death due to cancer.63 
 Of factors associated with treatment refusal, age at diagnosis was significantly associated 
with refusal of both chemoradiotherapy for LS-SCLC and chemotherapy for ES-SCLC. After 
adjusting for other characteristics, patients diagnosed at a younger age were less likely to refuse 
treatment compared with older patients. A meta-analysis among LS-SCLC suggested that due to 
the toxicity associated with chemoradiotherapy, the survival benefit from treatment was limited to 
younger patients.88  
 However, other studies have shown that both older and younger patients respond just as 
well to a combined modality therapy.89,90 A recent study using NCDB data suggested that older 
patients who received combined modality therapy had a better overall survival than for 
chemotherapy alone.134 Younger patients are considered to have better performance status, less 
comorbid conditions, and increased life expectancy, which are all factors that support the decision 
to agree to cancer treatment.135 Older patients, on the other hand, have increased concerns 
regarding the tolerability of chemotherapy, treatment duration and effectiveness, as well as 
comorbid conditions that affect the decision to decline the offered treatment.93,135 Analyses of the 
population and facility-based data in previous studies have shown a continuous increase in the 
proportion of SCLC patients diagnosed who were over the age of 70 years.136-138 If more SCLC 
patients are diagnosed at an older age, it may be reasonable to expect that the proportion of 
treatment refusal will continue to rise, due in part to the aforementioned array of concerns of 
older patients.  
 Regarding association with gender, previous studies have suggested an increased 
incidence of SCLC cases among women.139,140 Women with SCLC were also shown to have 





perceptions of cancer care.100,101 A recent study by Lee et al. showed that more women did not 
receive active cancer therapy (no treatment) for their initial treatment modality of SCLC.141 These 
findings are in agreement with our results, which suggested that women were more likely to 
refuse the recommended chemoradiotherapy for LS-SCLC and chemotherapy for ES-SCLC. 
Refusal linked to gender may occur because women with advanced cancer tend to value the 
quality of life more than just prolonging life.142 As also indicated in other cancer studies, women 
seemed to be more vulnerable to treatment toxicities than men, and were more likely than men to 
plan for other things in their end-of-life rather than repeatedly visiting medical facilities to 
complete cancer treatment series.100,143 These perceptions may affect women’s decisions to 
decline recommended cancer treatment. Our findings suggest the need for future studies to 
investigate the perception of SCLC treatment and expectations regarding their cancer treatment 
among women.  
 Uninsured patients were 2–3 times more likely to decline chemoradiotherapy for LS-
SCLC and to decline chemotherapy for ES-SCLC than those with private insurance. Other studies 
among lung cancer cases have been suggested that uninsured patients were more likely to refuse 
the offered cancer treatment.103,144 In addition, Halpern et al. also suggested that the uninsured 
were more likely to be diagnosed with advanced stage disease.103 The American Society of 
Clinical Oncology has raised concerns about inequities in cancer care due to insurance status.145 
A study by Duh et al. estimated that the average cost of IV chemotherapy for SCLC was $788 per 
visit or $9,449 per treatment course (three visits per cycle for four cycles).146 For uninsured 
patients, these costs may affect their decision to accept or decline recommended cancer treatment. 
Furthermore, any factor that delays treatment, could result in a more advanced and aggressive 
disease. To ensure delivery of quality cancer treatment and optimize patient outcomes, it is 
important to identify and remove impediments related to the health payer.  
 Results of survival analysis in this study demonstrate that the one-year survival of LS-





Among ES-SCLC, those who received chemotherapy were eight times more likely to survive for 
one year compared with those who refused recommended treatment. Similar to our study, Lally et 
al. and Behera et al. have previously suggested better survival rates among SCLC patients who 
received treatment than those who did not.136,147 Regardless of the benefit on survival of receiving 
treatment, patient autonomy and locus of control remain important aspects of care. Patient–
provider communication and patient education are essential in decision-making to increase 
patient acceptance of standard recommended treatment.  
 To our knowledge, our study is the most comprehensive one that has analyzed treatment 
refusal among SCLC patients using a national facility-based database. We specifically examined 
the treatment refusal of chemoradiotherapy for LS-SCLC and chemotherapy alone for ES-SCLC, 
as these have the strongest evidence bases as stage-specific recommended treatments modalities 
for SCLC patients. Our findings are relevant for patient management and future studies. The main 
strengths of our study are in the use of comprehensive clinical information including cancer stage 
and treatment recommendations, and a large sample size of SCLC cases included in our analyses. 
We used the database that includes approximately three-fourths of newly diagnosed cancer in the 
US population.107,112  
 The main limitations of our study are those seen with retrospective and database studies 
in general. Although the database covers a majority of cancer cases in the US, around 20% of 
newly diagnosed are not captured in the data.103 However, only marginal differences between 
NCDB and the SEER data have been acknowledged and should not meaningfully affect our 
findings.148 Our findings suggested the necessity for future studies to focus on factors that might 
contribute to treatment decision, for example patient–physician interactions, patient education 







 Although the proportion of patients refusing treatment for SCLC is relatively low, the 
increase in the treatment refusal over time is concerning. Older age at diagnosis, female gender, 
uninsured status, and comorbidities were associated with higher refusal of chemoradiotherapy 
among LS-SCLC and higher refusal of chemotherapy among ES-SCLC patients. It is important 
for health providers and policymakers to not only make good treatment recommendations but also 
consider the ways their recommendations are delivered to patients. Interventions targeting factors 
associated with higher treatment refusal may increase acceptance of recommended treatment and 





























+ Criteria are non-mutually exclusive 
  
Small cell lung cancer diagnosed between 2003–2012 in NCDB (N = 198,405) 
Excluded from sample selection (n=46,528)+ 
- Single or multiple cancer diagnoses and lung cancer was not the 
primary cancer (n = 32,158)  
- Non-invasive lung tumor (n = 1)  
- Diagnosed but did not receive any treatment from the reporting CoC 
facility (n = 17,400)  
 
n = 132,765 
Excluded from sample selection n = 24,777 because patients were not 
recommended either chemotherapy or radiation or combination of 
chemoradiotherapy as their first-course treatment for SCLC 
 
Sample size for analysis (n = 107,988) 
Excluded from sample selection (n = 19,112)+ 
- 13,817 patients were not having a confirmed stage at diagnosis 
- 186 Patients treated at “other” cancer programs 
- 5,756 patient insurance status listed as other government or unknown 
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Table 3. 1 Characteristics of Small Cell Lung Cancer Cases Who Received and Refused 
Treatment  
Characteristics 
Limited Stage+ (n = 30,585)  Extensive Stage++ (n = 31,679)  
Received 
n = 29,001  
n (%) 
Refused 
n = 409 
n (%) 
p value Received 
n = 29,792 
n (%) 
Refused 
n = 1,489 
n (%) 
p value 
Age at diagnosis (years)       
< 50  2,280 (7.9)  8 (2.0) < 0.001 1,736 (5.8) 34 (2.3) < 0.001 
50–70  18,950 (65.3) 142 (34.7) 17,886 (60.0) 573 (38.5) 
> 70  7,771 (26.8) 259 (63.3) 10,170 (34.1) 882 (59.2) 
Gender       
Male 12,816 (44.2) 156 (38.1) 0.014 15,566 (52.3) 651 (43.7) < 0.001 
Female 16,185 (55.8) 253 (61.9) 14,226 (47.8) 838 (56.3) 
Race       
White 25,972 (89.6) 362 (88.5) 0.470 27,047 (90.8) 1,358 (91.2) 0.542 
 Black  2,370 (8.2) 34 (8.3) 2,034 (6.8) 92 (6.2) 
Others/unknown 659 (2.3) 13 (3.2) 711 (2.4) 39 (2.6) 
Median Income Quartiles 
2008–2012 
      
< $ 38,000 6,290 (21.7) 100 (24.5) 0.101 6,188 (20.8) 317 (21.3) 0.664 
 $ 38,000–$ 47,999 8,116 (28.0) 118 (28.9) 7,924 (26.6) 398 (26.7) 
$ 48,000–$ 62,999 7,510 (25.9) 100 (24.5) 7,784 (26.1) 402 (27.0) 
$ 63,000 + 6,298 (21.7) 88 (21.5) 6,899 (23.2) 330 (22.2) 
Unknown 787 (2.7) 3 (0.7) 997 (3.4) 42 (2.8) 
Category Residence       
Metro counties 21,633 (74.6) 310 (75.8) 0.228 22,293 (74.8) 1,119 (75.2) 0.681 
 Urban counties 5,428 (18.7) 81 (19.8) 5,275 (17.7) 264 (17.7) 
Rural counties  723 (2.5) 9 (2.2) 781 (2.6) 43 (2.9) 
Unknown 1,217 (4.2) 9 (2.2) 1,443 (4.8) 63 (4.2) 
Insurance status       
Uninsured 1,262 (4.4) 17 (4.2) < 0.001 1,436 (4.8) 57 (3.8) < 0.001 
Private insurance 10,661 (36.8) 46 (11.3) 9,056 (30.4) 222 (14.9) 
Medicaid 2,416 (8.3) 24 (5.9) 2,421 (8.1) 75 (5.0) 
Medicare 14,662 (50.6) 322 (78.7) 16,879 (56.7) 1,135 (76.2) 
Charlson/Deyo Comorbid  
Conditions (CDCC) 
      
No comorbid condition 18,058 (62.3) 169 (41.3) < 0.001 16,269 (54.6) 664 (44.6) < 0.001 
Score 1 7,974 (27.5) 154 (37.7) 9,193 (30.9) 530 (35.6) 
Score 2 2,969 (10.2) 86 (21.0) 4,330 (14.5) 295 (19.8) 
CoC Facility       
Community Cancer Program 4,323 (14.9) 75 (18.3) 0.036 
 
4,438 (14.9) 218 (14.6) 0.002 
 Comprehensive Community 
Cancer Program 
17,704 (61.1) 254 (62.1) 17,941 (60.2) 959 (64.4) 
Academic/Research Program 6,974 (24.1) 80 (19.6) 7,413 (24.9) 312 (21.0) 
+ LS-SCLC patients who were recommended chemoradiotherapy, including those who did not receive for unknown reason 








Table 3. 2 Multivariable Logistic Regression of Factors Associated with Refusal of Small Cell 
Lung Cancer Treatment  
Characteristics AOR 95% CI p value 
Limited Stage – SCLC    
Age at diagnosis 
(years) 
50–70  Ref  < 0.001 
< 50  0.47 0.22–1.01 
> 70  3.50 2.77–4.44 
Gender Male Ref  0.016 
 Female 1.29 1.05–1.58 
Primary Payer Private insurance Ref  < 0.001 
No insurance 3.61 2.05–6.35 
Medicaid 2.50 1.51–4.12 
Medicare 2.41 1.72–3.38 
CDCC No comorbid Ref  < 0.001 
Score 1 1.86 1.49–2.33 
Score 2 2.54 1.94–3.31 
Extended Stage – SCLC 
   
Age at diagnosis 
(years) 
50–70  Ref  < 0.001 
< 50  0.73 0.51–1.04 
> 70  2.25 1.99–2.55 
Gender Male Ref  < 0.001 
Female 1.42 1.27–1.58 
Primary Payer Private insurance Ref  < 0.001 
No insurance 1.76 1.29–2.40 
Medicaid 1.32 1.01–1.74 
Medicare 1.72 1.46–2.02 
CDCC No comorbid Ref  < 0.001 
Score 1 1.29 1.15–1.46 
Score 2 1.43 1.23–1.65 
AOR = Adjusted odds ratio   CI: Confidence interval   
Note: In the final model variables race, category of residence, and facility were not significantly associated 







Table 3. 3 Multivariable Cox Regression of Factors Associated with Survival of SCLC Cases  
Characteristics AHR 95% CI p value 
Limited Stage – SCLC+ 
  
 
Age at diagnosis 
(years) 
50–70  Ref  < 0.001 
< 50  0.91 0.86–0.97 
> 70  1.27 1.23–1.32 
Gender Male Ref  < 0.001 
Female 0.82 0.79– 0.84 
Primary Payer Private insurance Ref  < 0.001 
No insurance 1.17 1.09–1.26 
Medicaid 1.20 1.14–1.27 
Medicare 1.18 1.14–1.23 
CDCC No comorbid Ref  < 0.001 
Score 1 1.18 1.14–1.21 
Score 2 1.36 1.30–1.43 
Facility Community  Ref  < 0.001 
Comprehensive 
Community 0.95 0.91–0.98 
Academic/Research  0.91 0.87–0.95 
Combination of 
chemoradiation 
Received Ref  < 0.001 
Refused 4.96 4.45–5.53 
Extended Stage – SCLC++   
 
Age at diagnosis 
(years) 
50–70  Ref  < 0.001 
< 50  0.95 0.90–1.00 
> 70  1.17 1.13–1.20 
Gender Male Ref  < 0.001 
Female 0.85 0.83–0.87 
Race White Ref  0.012 
Black  0.93 0.89–0.98 
Others/unknown 0.95 0.87–1.03 
Primary Payer Private insurance Ref  < 0.001 
No insurance 1.17 1.10–1.25 
Medicaid 1.11 1.06–1.17 
Medicare 1.12 1.09–1.16 
CDCC No comorbid Ref  < 0.001 
Score 1 1.16 1.13–1.20 
Score 2 1.41 1.36–1.47 
Facility Community Ref  0.005 
 Comprehensive 
Community  1.01 0.98–1.05 





Characteristics AHR 95% CI p value 
Combination of 
chemotherapy 
Received Ref  < 0.001 
Refused 3.69 3.48–3.92 
AHR = Adjusted hazard ratio  CI: Confidence interval  
+ LS-SCLC patients who were recommended chemoradiotherapy 
++ ES-SCLC patients who were recommended chemotherapy 
Note: In the final model variables category of residence was not significantly associated with survival 









FACTORS ASSOCIATED WITH REFUSAL OF RECOMMENDED 
TREATMENT BY PATIENTS WITH NON-SMALL CELL LUNG CANCER: 
AN ANALYSIS OF NATIONAL CANCER DATABASE 2003–2012 
 
Abstract  
Objectives: Refusal of recommended treatment contributes to a higher number of cancer-related 
deaths. Our study aimed to analyze factors associated with treatment refusal among non-small 
cell lung cancer (NSCLC) patients. Materials and Methods: We analyzed data on 884,817 
NSCLC patients from the National Cancer Database diagnosed between 2003 and 2012. The 
analysis of treatment refusal was carried out for surgery (stages I and II) and chemotherapy 
(stages III and IV). Logistic regression was used to investigate factors associated with treatment 
refusal. Results: Patients diagnosed at age < 50 years were less likely to refuse treatment than 
those age 50–70 years; the adjusted odds ratio (AOR) of treatment refusal comparing these two 
groups was 0.37 for surgery and 0.58 for chemotherapy. Compared with patients with private 
insurance, uninsured patients were more likely to refuse surgery (AOR = 2.47) and chemotherapy 
for stage III (AOR = 2.56) and IV (AOR = 2.50). Patients with comorbid conditions were less 
likely to refuse surgery for stage I and II (AOR = 0.87) but more likely to refuse chemotherapy 
for stage III (AOR = 1.94) and stage IV (AOR = 1.99). In comparison with those treated at 
community facilities, patients treated at academic facilities were less likely to refuse surgery 
(AOR = 0.45) and chemotherapy for stage III (AOR = 0.78), and stage IV (AOR = 0.68). 
Conclusions: Multiple patient and system-related factors, such as older age at diagnosis, 
comorbid conditions, and uninsured status, were associated with higher treatment refusal. 














 An estimated 234,030 new cases of lung cancer will be diagnosed in the US in 2018.12 
The disease is responsible for one in four cancer deaths; more than any other cancer in the US.12 
Many studies have reported the underuse of treatment modalities recommended to cancer 
patients, with lung cancer having higher treatment refusal rates in comparison to other 
cancers.63,95,97 Refusal of recommended cancer treatment is a contributing factor to cancer-related 
death and could be a potential cause for failure to achieve a significant reduction in lung cancer 
mortality.12,63,104  
 Previous studies that used cancer registry data have provided important insights; 
however, because of data limitations, they have not typically examined refusal of 
chemotherapy.45,71,148 The exclusion of chemotherapy is problematic as it is currently considered 
the most important treatment modality for advanced non-small cell lung cancer (NSCLC) and 
forms an integral part of care for patients with early and locally advanced disease.24,149 Although 
surgery provides an opportunity to cure nonmetastatic cancer, patient responses to this radical 
treatment are complex and need to be studied further.63 The primary purpose of our study was to 
examine factors associated with treatment refusal of surgery and chemotherapy by NSCLC 
patients.  
 
Materials and Methods 
Study Population, Design, and Data Source 
 Our study utilized the National Cancer Database (NCDB), a joint project of the American 
Cancer Society (ACS) and the Commission on Cancer (CoC) of the American College of 
Surgeons (ACoS). It serves as a nationwide cancer surveillance program that captures 





 In this cross-sectional study, all patients diagnosed with NSCLC between 2003 and 2012 
were eligible for inclusion in the analysis, with 1,237,129 NSCLC cases recorded in the database.  
We used the following eligibility criteria for sample selection: (1) diagnosed with a primary 
invasive lung cancer and (2) diagnosed at CoC-accredited facilities and received all/part of the 
treatment from CoC facilities. Figure 3.1 shows a flow chart of sample selection, with a final 
sample size of 884,817 after the application of inclusion criteria.  
Exposures and Outcomes  
 We included information on patient demographic and clinical characteristics as predictor 
variables and examined refusal of recommended treatment as the study outcome. The NCDB 
defines treatment refusal as a condition when patients refuse the standard therapy recommended 
by their physician. Patient responses were recorded for each therapy, e.g., surgery and 
chemotherapy, separately.111 If patients refused the recommended therapy, they were included in 
the refusal group; if there was no contraindication recorded, all others were included in the 
acceptance group. It should be noted that the NCDB does not record information regarding 
patients’ follow-up for a second opinion. The standard quality measures for evaluation of lung 
cancer directed-therapy in NSCLC used by the Veteran Health Administration include 
recommendations of curative surgery for stages I and II and recommendations for chemotherapy 
for stages III and IV.132 Therefore, we focused the treatment refusal analysis on these therapies 
for these respective stages.  
Statistical Analysis 
 We compared demographic and clinical characteristics of patients who refused to those 
who accepted the recommended therapy. A bivariate analysis was conducted to examine potential 
association of predictor variables with an outcome, i.e., refusal of surgery or refusal of 





in the bivariate analysis or variables that are important from a clinical or biological standpoint 
were included in multivariable analyses.  
 Predictors included in multivariable logistic regression analysis were: age at diagnosis, 
gender, race, primary payer, residence category, histologic type, tumor size, comorbid conditions, 
and facility type. The dataset was partitioned into three parts according to cancer stage: refusal of 
surgery for stages I and II, refusal of chemotherapy for stage III, and for refusal of chemotherapy 
for stage IV. All tests were two-sided, with a p-value < 0.05 considered statistically significant. 
All analyses were conducted using the SAS software version 9.4 (SAS Institute; Cary, NC). 
Confidentiality and Ethics 
 The data used in the present study were derived from a de-identified NCDB file. Results 
reported in this study are in compliance with the privacy requirements of the Health Insurance 
Portability and Accountability Act of 1996. The ACS and CoC have not verified, and neither is 
responsible for the analytic and statistical methods utilized in this study. The statements made in 
the discussion and the conclusions drawn from these data are solely those of the investigators. 
Given that it uses existing and de-identified data, this study has been classified as exempt by the 
Institutional Review Board of University of Nebraska Medical Center.   
 
Results 
 Demographic and clinical characteristics of NSCLC patients are presented in Table 4.1. 
The cohort included predominantly White patients (85%). There was a male preponderance 
(53%), and 51% of patients were diagnosed between 50 and 70 years of age. The majority of 
patients were covered by Medicare (57%) and private insurance (29%), while approximately 4% 
were uninsured. More than half of patients were diagnosed with advanced stages, specifically 





 Of the 257,811 patients diagnosed with stages I and II, surgery was recommended for 
73%. There were 199,166 patients diagnosed with stage III and 354,892 diagnosed with stage IV. 
Chemotherapy was recommended for 69% and 57% of these patients, respectively (data not 
shown). Figure 3.2 shows a higher proportion of treatment refusal as the stage increased; the 
proportion of patients who refused treatments ranged from 2–9%.  
 Among patients diagnosed with stages I and II, and for whom surgery was recommended, 
a higher percentage of older-onset patients (age > 70 years) refused treatment (71%) (Table 4.2). 
A higher proportion of those who were covered by private insurance agreed to undergo surgery, 
while a lower proportion of patients with Medicare agreed (p < 0.001). Interestingly, patients with 
no comorbid conditions were more likely to refuse surgery. Patients without comorbidity were 
more likely to agree to the recommended chemotherapy than those with comorbid conditions (p < 
0.001).  
 Results of the multivariable analysis are presented in Table 4.3. Compared with 
intermediate-onset patients (age 50–70 years), patients diagnosed at younger-onset (age < 50 
years) were less likely to refuse treatment, while older-onset patients were more likely to refuse 
treatment. The adjusted odds ratio (AOR) was 0.37 for refusal of surgery (95% CI: 0.28–0.49) 
and AOR = 0.58 for refusal of chemotherapy for stage III (95% CI: 0.49–0.68). Uninsured 
patients were more likely to refuse treatment than those with private insurance, with the AOR 
being 2.47 for refusal of surgery (95% CI: 1.89–3.20) and AOR = 2.56 for refusal of 
chemotherapy for stage III (95% CI: 2.19–2.98) and AOR = 2.50 for stage IV (95% CI: 2.27–
2.75).  
 Patients with comorbid conditions were less likely to refuse surgery, but more likely to 
refuse chemotherapy. In addition, we found that patients treated at academic facilities were less 





0.78; 95% CI: 0.72–0.86; and for stage IV AOR = 0.68; 95% CI: 0.64–0.73). Potential interaction 
of race with insurance status was examined, and we found no significant association. 
 
Discussion 
 This study is one of a very limited number of studies that have examined the association 
of various factors related to treatment refusal among NSCLC patients. The analysis of refusal of 
surgery and chemotherapy in this study delineate comprehensive care of patients with early and 
advanced stages of lung cancer. Using similar category of treatment refusal, analyses of 11 cancer 
sites, including lung cancer by Ward et al., suggested that surgery and chemotherapy were the 
most commonly refused treatment modality.95 Our results showed that the proportion of treatment 
refusal ranged from 2–9%. Use of a national facility-based cancer registry enabled us to analyze 
more clinical data than previous studies.  
 We found that older-onset patients were three times more likely to refuse surgery or 
chemotherapy than intermediate-onset patients. Similar findings were reported in studies of early-
stage NSCLC patients.97,99,132 De Rijke et al. reported that older age (75+ years) was the most 
important factor for patients not to receive standard treatment.125 Among the older-onset patients, 
treatment refusal was frequently affected by fear of toxicity or treatment side effects, treatment 
duration, and patient beliefs about the effectiveness of the treatment offered.92,93,99,150 A 
systematic review of patients’ decisions in cancer treatment showed that older adults might 
choose the quality of life over survival prolongation.93 In addition, older patients might have other 
diseases in addition to cancer that could affect treatment tolerability, effectiveness, and life 
expectancy.93,99 Differences in priorities and comorbidities among older patients influence their 





 Findings on the effect of gender have been mixed. Our analysis found no difference in 
surgical refusal between males and females with early-stage cancer. Similar findings have been 
reported in previous studies.99,131 However, among patients diagnosed with stage III and stage IV 
and recommended chemotherapy, we observed that women were more likely to refuse treatment 
than men. Findings from a multisite cohort study among patients with advanced cancer also 
reported that women were less likely than men to agree to aggressive end-of-life treatments.142 
Explanations of the differences among patients with advanced cancer stages seem related to the 
individual patient’s view of life, their values, and personal judgment. Women appeared more 
likely to understand that they had an incurable disease, which influenced their decision to forgo 
the treatment.100 A different study among severely ill patients, including some cancer patients, 
suggested that women were more likely to believe that medical recommendations were only for 
comfort care rather than intended to prolong life.101 
 The American Society of Clinical Oncology has highlighted the issue of significant 
inequities in cancer care related to insurance status.145 Previous studies have reported that lung 
cancer was among cancers with a high prevalence of uninsured cases in the US.103,144 Our study 
found that 55,465 patients were on Medicaid and 33,254 patients were uninsured. Our analysis 
further revealed that patients without insurance and those on Medicaid were 2–3 times more 
likely to refuse surgery or chemotherapy than those with private insurance. 
 A national study of pathology and patterns of NSCLC care suggested that 
recommendation for surgery was determined more by cancer stage and patients’ age than by 
comorbidity.151 Conversely, other studies found that comorbid conditions were associated with a 
higher surgical refusal.99,132,152 Our study found that patients without comorbidity were more 
likely to refuse surgery than those with comorbidity. It is possible that patients without 
comorbidity believe they are healthier and, therefore, choose to seek a second opinion before 





decision to have it might be affected by other nonclinical factors such as access to medical care, 
patient–physician interactions, and patient perception of the necessity of surgery.99,132,153,154 As 
reported by Bradley et al., the length of stay and cost of inpatient care influence patients’ 
decisions concerning whether or not to accept surgery, especially for those who are uninsured and 
underinsured.155 The influence of these factors on patients’ decisions to decline recommended 
treatment requires further investigation in future studies.  
 Finally, previous studies in lung cancer have reported that due to problems in accessing 
health facilities, those living in rural areas were more likely to refuse the treatment options than 
patients residing in urban area.132,154 However, our study did not find this association, possibly 
due to a small proportion of patients coming from rural areas. 
 A few limitations of the study should be considered for interpretation of the study 
findings. About 20–25% of newly diagnosed cancer patients are treated at non-CoC facilities that 
are not part of the NCDB data.103 However, Mettlin et al. reported marginal differences in patient 
and treatment characteristics between Surveillance, Epidemiology and End Results (SEER) and 
the NCDB.148 The wide coverage and diverse nature of the CoC facilities, as well as the small 
differences, contribute to our confidence in the generalizability of the study findings. Another 
limitation of the NCDB data was that factors that may contribute to treatment refusal, such as 
patient’s social support, patient–physician interactions, and level and type of psychological 




 Multiple patient and system-related factors, such as older age at diagnosis, comorbid 





these factors is essential to develop strategies for patient education and patient–provider 
communication. Further investigations are needed to identify the beneficial treatments that cover 





Table 4. 1 Patient Demographic and Clinical Characteristics 
 
  
Characteristics Total NSCLC cases  Characteristics Total NSCLC cases N = 884,817 %  N = 884,817 % 
Age at diagnosis (years)    Tumor size (cm)  
< 50  57,674 6.5  < 3   285,149 32.2 
50–70  449,339 50.8  3–7  309,134 34.9 
> 70  377,804 42.7  > 7  85,714 9.7 
Gender    Tumor involvement at lung  1,591 0.2 
Male 471,891 53.3  Unknown 203,229 23.0 
Female 412,926 46.7  Charlson/Deyo Comorbid  
Conditions (CDCC)$ 
Race    No comorbid condition 524,606 59.3 
White 750,676 84.8  Score 1 248,723 28.1 
Black  101,436 11.5  Score 2 111,488 12.6 
Others/unknown 32,705 3.7  Histology   
Primary Payer    Non-small cell carcinoma 150,323 17.0 
Uninsured 33,254 3.8  Squamous cell carcinoma 214,879 24.3 
Private insurance 255,058 28.8  Adenocarcinoma 368,423 41.6 
Medicaid 55,465 6.3  Large cell carcinoma  30,363 3.4 
Medicare 506,989 57.3  Others  120,829 13.7 
Other government  11,278 1.3     
Unknown  22,773 2.6  CoC Facility   
Median Income Quartiles  
2008–2012 
 
Community  106,766 12.1 
< $ 38,000 185,912 21.0  Comprehensive Community 499,651 56.5 
$ 38,000–$ 47,999 222,090 25.1  Academic/Research 277,276 31.3 
$ 48,000–$ 62,999 226,808 25.6  Other cancer programs 1,124 0.1 
$ 63,000 +  224,291 25.4  First course treatment   
Unknown 25,716 2.9  Surgery 167,109 18.9 
Category Residence    Radiotherapy 126,556 14.3 
Metro counties 691,638 78.2  Chemotherapy 108,457 12.3 
Urban counties 135,567 15.3  Surgery and chemo and/or 
radiotherapy 
80,520 9.1 
Rural counties  18,489 2.1 
Unknown 39,123 4.4  Chemotherapy and 
radiotherapy 
196,902 22.3 
AJCC analytic stage    No surgical, chemo or 
radiotherapy received 
196,022 22.2 
Stage I  193,098 21.8 
Stage II 64,713 7.3  Unknown 9,251 1.1 
Stage III 199,166 22.5     
Stage IV 354,892 40.1     
Missing+ 72,948 8.2     





Table 4. 2 Characteristics of Patients Who Accepted vs. Refused Recommended Treatment: Surgery for Stage I-II, and 
Chemotherapy for Stage III-IV  
Characteristics 
Stage I and II –  
recommended surgery p value 
Stage III and IV –  
recommended chemotherapy  p value Accepted Refused Accepted Refused 
n = 181,721 % n = 4,313 % n = 300,519 % n = 27,452 % 
Age at diagnosis (years)       
< 50  10,540 5.8 60 1.4 < 0.001 28,982 9.6 886 3.2 < 0.001 
50–70  100,293 55.2 1,174 27.2 183,158 61.0 10,207 37.2 
> 70  70,888 39.0 3,079 71.4 88,379 29.4 16,359 59.6 
Gender           
Male 88,514 48.7 2,089 48.4 0.722 
 
167,820 55.8 13,779 50.2 < 0.001 
Female 93,207 51.3 2,224 51.6 132,699 44.2 13,673 49.8 
Race           
White 160,718 88.4 3,569 82.8 < 0.001 251,503 83.7 23,518 85.7 < 0.001 
Black  14,821 8.2 575 13.3 37,138 12.4 2,899 10.6 
Others/unknown 6,182 3.4 169 3.9 11,878 4.0 1,035 3.8 
Primary Payer       
Uninsured 3,498 1.9 76 1.8 < 0.001 13,659 4.6 1,237 4.5 < 0.001 
Private insurance 60,227 33.1 527 12.2 110,836 36.9 4,521 16.5 
Medicaid 7,737 4.3 211 4.9 22,961 7.6 1,935 7.1 
Medicare 104,808 57.7 3,388 78.6 141,223 47.0 19,015 69.3 
Other government  1,632 0.9 45 1.0 4,058 1.4 271 1.0 
Unknown  3,819 2.1 66 1.5 7,782 2.6 473 1.7 
Median Income Quartiles  
2008–2012   
     
< $ 38,000 33,416 18.4 999 23.2 < 0.001 60,778 20.2 6,194 22.6 < 0.001 
$ 38,000–$ 47,999 44,258 24.4 1,120 26.0 74,523 24.8 7,279 26.5 
$ 48,000–$ 62,999 47,772 26.3 1,110 25.7 77,712 25.9 6,970 25.4 
$ 63,000 +  52,117 28.7 1,016 23.6 78,092 26.0 6,325 23.0 
Unknown 4,158 2.3 68 1.6 9,414 3.1 684 2.5 
Category Residence        
Metro counties 142,594 78.5 3,406 79.0 0.066 233,671 77.8 21,470 78.2 < 0.001 
Urban counties 28,246 15.5 690 16.0 46,515 15.5 4,359 15.9 
Rural counties  3,722 2.1 76 1.8 6,463 2.2 594 2.2 






Stage I and II –  
recommended surgery p value 
Stage III and IV –  
recommended chemotherapy  p value Accepted Refused Accepted Refused 
n = 181,721 % n = 4,313 % n = 300,519 % n = 27,452 % 
Tumor size (cm)           
< 3  112,687 62.0 2,202 51.1 < 0.001 67,966 22.6 5,737 20.9 < 0.001 
3–7 58,503 32.2 1,629 37.8 116,028 38.6 10,614 38.7 
> 7  8,325 4.6 186 4.3 37,415 12.5 3,533 12.9 
Tumor involvement at lung  9 0.0 0 0.0 683 0.2 92 0.3 
Unknown 2,197 1.2 296 6.9 78,427 26.1 7,476 27.2 
CDCC           
No comorbid condition 93,470 51.4 2,477 57.4 < 0.001 202,250 67.3 14,430 52.6 < 0.001 
Score 1 64,179 35.3 1,185 27.5 72,208 24.0 8,467 30.8 
Score 2 24,072 13.3 651 15.1 26,061 8.7 4,555 16.6 
Histology           
Non-small cell carcinoma 8,439 4.6 660 15.3 < 0.001 65,275 21.7 4,833 17.6 < 0.001 
Squamous cell carcinoma 53,797 29.6 1,119 25.9 69,056 23.0 5,998 21.9 
Adenocarcinoma 97,382 53.6 1,213 28.1 133,709 44.5 9,722 35.4 
Large cell carcinoma 6,148 3.4 78 1.8 11,427 3.8 862 3.1 
Others  15,955 8.8 1,243 28.8 21,052 7.0 6,037 22.0 
CoC Facility           
Community  15,050 8.3 659 15.3 < 0.001 37,828 12.6 4,226 15.4 < 0.001 
Comprehensive 
Community 
101,367 55.8 2,474 57.4 166,419 55.4 16,686 60.8 
Academic/Research  64,942 35.7 1,173 27.2 95,898 31.9 6,495 23.7 







Table 4. 3 Multivariable Logistic Regression of Factors Associated with Treatment Refusal  
 
Characteristics 
Refusal of Surgery  
(stage I and II)  
Refusal of Chemotherapy  
(stage III) 
Refusal of Chemotherapy  
(stage IV) 
AOR 95% CI AOR 95% CI AOR 95% CI 
Age at diagnosis (years)  p < 0.001  p < 0.001  p < 0.001 
50–70  Ref  Ref  Ref  
< 50  0.37 0.28 - 0.49    0.58 0.49 - 0.68 0.58 0.52 - 0.64 
> 70  3.42 3.15 - 3.71 3.16 2.97 - 3.37 2.68 2.56 - 2.81 
Gender  p =  0.056  p < 0.001  p < 0.001  
Male Ref  Ref  Ref  
Female 1.07 1.00 - 1.14 1.31 1.24 - 1.38 1.25 1.20 - 1.30 
Race  p < 0.001  p = 0.019  p = 0.192 
White Ref  Ref  Ref  
Black  2.25 2.04 - 2.49 1.06 0.98 - 1.15 0.99 0.93 - 1.05 
Others/unknown 1.42 1.19 - 1.68 1.20 1.04 - 1.38 1.09 0.99 - 1.21 
Primary Payer  p < 0.001  p < 0.001  p < 0.001 
Private insurance Ref  Ref  Ref  
No insurance 2.47 1.89 - 3.20 2.56 2.19 - 2.98 2.50 2.27 - 2.75 
Medicaid 3.09 2.59 - 3.69 2.26 2.00 - 2.56 2.12 1.96 - 2.31 
Medicare 2.04 1.84 - 2.27 1.75 1.61 - 1.89 1.69 1.60 - 1.79 
Other government  2.92 2.10 - 4.04 1.55 1.21 - 1.98 1.48 1.20 - 1.82 
Category Residence  p = 0.249  p = 0.797  p = 0.455 
Metro counties Ref  Ref  Ref  
Urban counties 0.99 0.90 - 1.08 0.98 0.91 - 1.05 0.98 0.93 - 1.03 
Rural counties 0.81 0.63 - 1.04 0.96 0.81 - 1.14 0.94 0.82 - 1.07 
Histology  p < 0.001  p < 0.001  p < 0.001 
Adenocarcinoma Ref  Ref  Ref  
Non-small cell carcinoma 6.16 5.54 - 6.85 1.12 1.04 - 1.21 1.05 1.00 - 1.11 
Squamous cell carcinoma 1.43 1.31 - 1.57 1.22 1.14 - 1.31 1.21 1.15 - 1.28 
Large cell carcinoma 1.08 0.84 - 1.37 0.96 0.82 - 1.12 1.18 1.06 - 1.32 
Others  7.44 6.82 - 8.12 3.90 3.59 - 4.23 4.16 3.95 - 4.39 
Tumor size (cm)  p < 0.001  p = 0.015  p < 0.001 
< 3   Ref  Ref  Ref  
3–7 1.33 1.24 - 1.42 1.06 1.00 - 1.13 1.06 1.01 - 1.11 






Refusal of Surgery  
(stage I and II)  
Refusal of Chemotherapy  
(stage III) 
Refusal of Chemotherapy  
(stage IV) 
AOR 95% CI AOR 95% CI AOR 95% CI 
Tumor involvement at the  lung < 0.001 < 0.001 - ∞ 1.90 0.93 - 3.89 1.53 1.19 - 1.96 
CDCC  p < 0.001  p < 0.001  p < 0.001 
No comorbid Ref  Ref  Ref  
Score 1 0.64 0.59 - 0.69 1.42 1.34 - 1.51 1.48 1.42 - 1.55 
Score 2 0.87 0.79 - 0.96 1.94 1.81 - 2.09 1.99 1.88 - 2.11 
Facility  p < 0.001  p < 0.001  p < 0.001 
Community  Ref  Ref  Ref  
Comprehensive Community  0.57 0.52 - 0.63 0.97 0.90 - 1.05 0.91 0.86 - 0.96 
Academic/Research  0.45 0.40 - 0.50 0.78 0.72 - 0.86 0.68 0.64 - 0.73 
Other cancer programs 0.75 0.35 - 1.62 1.18 0.62 - 2.26 1.04 0.65 - 1.66 


















Non-small cell lung cancer diagnosed between 2003–2012 in NCDB (N = 1,237,129) 
Excluded from sample selection: 
- Multiple cancer diagnoses and lung cancer was not the primary 
cancer (n = 266,396)  
- Non-invasive lung tumor (n = 1,542)  
- Diagnosed but did not receive any treatment from the reporting 
CoC facility (n = 108,822)  



































DISCUSSION AND CONCLUSIONS  
 
 Lung cancer is a major cause of cancer morbidity and mortality in the US. The estimation 
made in 2018 suggests that lung cancer diagnosis is the second most commonly diagnosed cancer 
in both genders.11 Although many improvements in diagnosis and treatments have been 
achieved,5,11,13 the number of deaths due to lung cancer is still high. For both genders, lung cancer 
is causing 25% of all cancer-related deaths.11,12 Recent report indicate the relative five-year 
survival rate of lung cancer is only 18%.11 Because of the great burden of lung cancer, 
investigating and examining factors associated with survival are essential to suggest areas of 
improvement in lung cancer care.  
 This dissertation focused on investigating factors associated with the survival of lung 
cancer patients through three specific aims. First, we examined the survival of NSCLC patients 
and analyzed factors associated with the survival. Second, we investigated the effect of treatment 
refusal on the survival of SCLC patients and factors associated with treatment refusal by patients. 
Lastly, we investigated factors associated with treatment refusal of NSCLC patients.  
 
Study Findings and Its Relevance to Literature 
 Earlier findings suggest that individuals with different age at diagnosis of lung cancer 
have different characteristics, such as cancer stage, type of tumor, and genetic susceptibility.44,45,47 
Our results included in Chapter 2 demonstrate that a higher proportion of patients among the 
younger-onset patients were diagnosed at advanced stages, had a positive family history of 
cancer, were current smokers, and had adenocarcinoma histology than the older-onset cases. 





patients from the analyses of population and facility-based data.45,47,79 Patients diagnosed with 
lung cancer at different age have different characteristics.44,45,47 
 Studies reported that many of the younger-onset lung cancer patients were typically 
symptomatic and diagnosed at an advanced stage.42,48,86 One explanation may be that a younger 
patient is less likely to think that he or she could have developed lung cancer at a younger than 
typical age. These young people perhaps pay less attention to the respiratory symptoms and 
present later to their providers. In addition, a general practitioner may suspect less about a 
younger patient to have lung cancer than an older patient with similar symptoms. This condition 
may delay the health provider in ordering diagnostic tests to detect lung cancer.  
 Previous studies also indicate that the late diagnosis among young lung cancer patients 
was due to issues with not having insurance, being underinsured, and having limited access to 
cancer care.103,105,106 It is also possible that because of the social perception that lung cancer is a 
self-inflicted disease, it may hinder young patients to take a lung cancer screening. Consequently, 
these young patients ended up being diagnosed with lung cancer at an advanced stage. Lung 
cancer is mostly known as a disease of older people, but the literature suggests that a substantial 
number of lung cancer cases occur before the age of 50 years.12,17,41,42 Studies defined this group 
of patients as younger-onset lung cancer cases.17,31,34 The observed proportion of younger-onset 
lung cancer in the databases that we used, the VACCR and the NCDB data, were 2.4% and 6.5%, 
respectively. Those proportions we observed were relatively similar to previous studies.47,79 
 The survival of lung cancer patients has been examined in previous studies and results 
suggest multiple factors were associated with survival including age at diagnosis.45,47,48,79 
However, the direction of the association between age at diagnosis and patients’ survival has been 
inconclusive. Among the veterans population, our results show that the overall five-year survival 





These results corroborate findings from earlier studies suggesting a higher survival among 
younger-onset patients than older-onset patients.45,47,79  
 While multiple factors were associated with overall survival, our results indicate that age 
at diagnosis and cancer stage were factors that strongly influenced patients’ survival. Notable 
differences in clinical and statistical results that suggest a better five-year survival among the 
younger-onset were shown among early-stage (I and II) patients, whereas among advanced stage 
(III and IV) patients, only a marginal difference in survival was seen between the younger- and 
older-onset. It is likely that the disease aggressiveness at advanced stages of NSCLC lowers the 
overall survival of both younger-and older-onset patients.  
 Previous studies also suggest that the fewer comorbidities and a better performance status 
among younger-onset patients were contributed to a better survival.41,45,46 Younger patients are 
typically healthier; thus, physicians were more likely to recommend them for an aggressive 
treatment, including surgery than older patients. In addition, it is likely that comorbidities 
associated with increasing age lead to lower survival in the older patients. Unfortunately, the 
VACCR database that we analyzed does not capture clinical information such as comorbid 
conditions and patient performance status. The availability of more comprehensive information 
will enable us to better explain the higher survival among younger-onset patients.  
 Treatment decline was another factor suggested as being directly associated with cancer-
related deaths.63,104 However, that information is still not convincing enough for lung cancer 
patients to take the recommended treatment. Of all lung cancer cases, the SCLC patients are well 
known to have the least five-year survival rates. A recent report indicates the five-year survival 
rate of SCLC was less than 7%.12  
 In Chapter 3, we present our results on survival analyses according to typical 
recommended therapies for patients diagnosed at different cancer stages for SCLC: LS-SCLC and 





chemoradiotherapy; whereas, ES-SCLC cases are predominantly treated with 
chemotherapy.55,126,128 The results of our analyses among SCLC patients suggest that patients who 
received the recommended treatment had a significantly higher survival than those who declined 
the treatment, both in LS-SCLC and ES-SCLC. The overall median survival of SCLC patients 
was 9.4 months. Our results show that among LS-SCLC patients who were recommended 
chemoradiotherapy, the median survival of patients who refused and received the treatment was 3 
and 18 months, respectively. For ES-SCLC patients, the median survival of those who refused 
chemotherapy was 1 month compared with 7.5 months of patients who received therapy. 
 Our findings were consistent with previous studies that suggested better survival rates 
among SCLC patients who received treatment than those who declined.136,147 In multivariable 
analyses using the Cox PH regression, our results show that younger age, female gender, private 
insurance, no comorbid conditions, and acceptance of cancer treatment were associated with 
lower risk of mortality. Of those factors, treatment refusal demonstrates a profound effect. Of LS-
SCLC patients who were recommended chemoradiotherapy, those who declined treatment had 
five times higher risk of mortality than those who received treatment. Similarly, among ES-SCLC 
patients who were recommended chemotherapy, patients who refused treatment had about four 
times higher risk of mortality than those who received treatment. A better survival may have 
resulted from a combination of multiple factors, however, it is likely that acceptance of treatment 
may increase patient life expectancy. Nevertheless, we have to acknowledge that the existence of 
barriers in the use of optimal lung cancer care is a complex condition. Many factors may play a 
role in the final decision for lung cancer care including diagnostic tests, patient preference, 
cultural aspects, and provider judgment.  
 Studies have reported a higher rate in underuse of treatment modalities among lung 
cancer patients than other cancers.63,95,97 Treatment refusal is an important reason for 





factors associated with treatment refusal among lung cancer patients are lacking. Our results 
showed factors that associated with treatment refusal among the early and advanced stages lung 
cancer patients and those factors can suggest areas of improvement in lung cancer care.  
 In Chapter 3, our results show that a majority of first-course treatments received by 
SCLC patients were according to the clinical practice guidelines. The overall refusal of 
recommended chemoradiotherapy among LS-SCLC patients was 1.34% and the refusal of 
chemotherapy among ES-SCLC patients was 4.7%. Over 10 years of data, we observed an 
increase in proportions of treatment refusal among SCLC cases, especially ES-SCLC patients. 
With approximately 75% of SCLC cases diagnosed with ES-SCLC, issues associated with 
treatment refusal deserve attention in regard to the lethality of this type of cancer.  
 For NSCLC, the current guidelines indicate surgery as the primary treatment for operable 
early-stage cancer (stages I and II).156 For advanced stage cancer, treatment options may include a 
combination of chemotherapy, palliative radiation, and targeted therapy.13,52 The results presented 
in Chapter 4 suggest that 2% to 9% of NSCLC patients refused the recommended treatment and a 
higher proportion of refusal was seen among patients with advanced stages. Furthermore, we 
observed multiple patient and system-related factors that were associated with patient decision to 
refuse recommended treatment. Of those factors, older age at diagnosis, female gender, comorbid 
conditions, and uninsured status were strongly associated with higher treatment refusal. We could 
not explore more about the aforementioned factors in this study as the variables in the database 
are limited; however, our literature review may suggest possible reasons for the factors we 
observed. Another limitation, because the data do not have follow up information for treatment 
refusal, we cannot assessed if the patient made changes in their decision.  
 Despite the fact that previous studies have shown both older and younger patients 
respond just as well to combined modality therapy,89,90 older-onset lung cancer patients were 





support young patients to agree to cancer treatment were their overall health status and less 
comorbid conditions.135 In contrast, older-onset patients have increased concerns regarding their 
tolerability to treatment, duration and effectiveness of treatment, and comorbid conditions that 
eventually influenced their decision to decline the offered treatment.93,135 Other studies also 
suggest that older-onset patients might not see their chance to be curable, thus they opt out of the 
recommended treatment.93 It has also been reported that older patients may not receive enough 
information about treatment options and its benefits that discourage them from taking 
treatment.157,158 Statistics have been shown demographic shift toward an older population and 
with majority of lung cancer cases diagnosed at older age, it may explain the increase pattern of 
treatment refusal.  
 Results of our analyses suggest that women, especially those with advanced stage lung 
cancer, were more likely to refuse the recommended therapies. Differences according to gender 
may be related to patients’ perceptions of cancer care.100,101 Previous studies suggest that women 
with advanced stages cancer tend to refuse the treatment options due to nonclinical reasons such 
as they prefer the quality of life more than prolonging life142 and tend to plan for other things in 
their end-of-life rather than to complete cancer treatment series.100,143 In addition, earlier studies 
reported that women were clinically more vulnerable to treatment toxicities than men.100,143 
Understanding concerns associated with treatment refusal among women is important in regard to 
incidence rates of lung cancer among women.12  
 From the analyses of NCDB data on treatment refusal, we observed an interesting finding 
that patients without comorbidity were more likely to decline surgery than those with comorbidity 
among early-stage cancer. We cannot further analyze the comorbid conditions that were 
associated with the refusal because the database only included information about comorbidity 
scores. Literature suggests that patients were considering surgery as a radical treatment, and their 





physician interactions, and patient perception of the necessity of surgery.99,132,153,154 A qualitative 
study by George et al. suggested that following the surgical recommendation, lung cancer patients 
usually searched for a second opinion before making a plan to take the option.153 The length of 
stay and cost of inpatient care associated with surgery were some of the factors that concerned 
patients, particularly for patients without an insurance plan.155 
 In regard to insurance, our results suggest that uninsured and Medicaid patients were two 
to three times more likely to refuse either surgery or chemotherapy than those with private 
insurance. Similar findings to our results have been reported by previous studies.159 Concerns 
about treatment cost and limited insurance coverage were indicated by different studies resulting 
in a lack of diagnostic and therapeutic cancer care received by uninsured and underinsured 
patients.103,160 The issue for non-optimal cancer care associated with insurance status has caused a 
substantial concern that the American Society of Clinical Oncology highlighted it as the issue of 
significant inequities in cancer care.145 To achieve equity in health care, approaches to remove the 
barriers such as access to lung cancer screening and treatment need to be addressed.  
 
Implication of Current Research 
 Findings from this dissertation emphasize the importance of understanding factors 
associated with survival and patient decision for lung cancer treatment. Our focus on age at 
diagnosis would not only explain the influences over disease prognosis but also offer 
explanations related to the patient’s view of life, their values, and personal judgment.  
 Our results demonstrated that more of the younger-onset group patients were diagnosed 
at advanced stages. The results may indicate issues on access to lung cancer screening, especially 
among young patients. Improvements, such as providing a better access for lung cancer screening 





 In addition, a higher survival observed among younger-onset patients could be a point of 
interest for health providers and health system. The possibilities that younger-onset patients have 
better health performance, fewer comorbidities, and higher acceptance to treatment may enable 
health providers to recommend more diverse treatment options. Identifying and treating younger-
onset lung cancer patients may be a point to improve the survival and to reduce mortality rates of 
lung cancer.  
 To improve patients’ survival in relation to treatment refusal, our results in Chapters 3 
and 4 may suggest points to enhance in patient education and patient–provider communication. 
Our data indicate that older-onset patients, having comorbid conditions, and being uninsured were 
more likely to refuse recommended treatment. Thus, it is important to inform patients with these 
characteristics about treatment options and its benefits including palliative treatment that essential 
for patients in making their decision. Although the majority of patients with advanced stage lung 
cancer cannot be cured, they can still make plans of their interest in end-of-life. Options for less 
toxic treatment regimens or palliative care that may improve patient quality of life should work 
better than having no treatment. 
 
Suggested Future Research 
 Findings presented in this dissertation are expected to add more information to the 
existing body of literature on lung cancer research. With the higher burden of morbidity and 
mortality of lung cancer, more research should be directed to address gaps in identifying and 
treating patients. We have included some suggestions that may be focused in future studies. 
 The results indicate that younger-onset patients were more likely diagnosed at advanced 
stages. It is possible because the lack of attention to their health caused these younger people to 





related to detoxifying reactive metabolites of tobacco smoke procarcinogens among young 
patients with genetic polymorphisms of glutathione S-transferases exposed them to a higher risk 
of developing cancer.34 Different studies indicate that lung cancer patients diagnosed at less than 
50 years of age have predisposing genetic factors.33,49,50 To better understand the risk for younger-
onset lung cancer, future research should try to identify genetic features that are more prevalent 
among the younger-onset than the older-onset. In addition, results also showed that younger-onset 
patients presented more with adenocarcinoma histology and positive family history of cancer. 
Further investigations into tumor molecular characteristics or genetic mutations are needed to 
explain lung cancer at a younger age and potential targeted therapies. 
 In our discussion of factors associated with survival, databases that we used for this 
dissertation do not include comprehensive information that may better explain the findings. 
Further research should include factors such as types of comorbidities, patient performance status, 
exposures from smoking, amount of smoking, and other environmental factors to present a more 
comprehensive understanding on profound factors associated with the survival of lung cancer 
patients. 
 The current research found that younger-onset lung cancer patients obtained the greatest 
benefits of treatment because they are relatively eligible for aggressive treatment and are less 
likely to refuse treatment in comparison to the older patients. Future research needs to evaluate 
this further and see if improvement in survival could also be achieved by increasing awareness 
about lung cancer risk factors and improving access to screening and treatment of lung cancer. 
For the older-onset group, more work should see if by improving patient education and patient–
physician communication, more patients are taking the recommended treatment. In addition, 
future studies should aim to identify the most beneficial treatment for lung cancer that addresses 







The results of this dissertation suggest that multiple factors were associated with patients’ 
survival including age at diagnosis and treatment refusal. The younger-onset patients had a better 
survival and were less likely to refuse recommended treatments than the older-onset patients. Our 
findings support the notion of better access for lung cancer screening, patient education, and 
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